Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
4-20-2011 12:00 AM

On the early onset of vascular stiffening and sexual dimorphism
of sympathetic control in the spontaneously hypertensive rat
Louis Mattar, The University of Western Ontario
Supervisor: J. Kevin Shoemaker, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Kinesiology
© Louis Mattar 2011

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Systems and Integrative Physiology Commons

Recommended Citation
Mattar, Louis, "On the early onset of vascular stiffening and sexual dimorphism of sympathetic control in
the spontaneously hypertensive rat" (2011). Electronic Thesis and Dissertation Repository. 125.
https://ir.lib.uwo.ca/etd/125

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

On the early onset of vascular stiffening and sexual dimorphism of
sympathetic control in the spontaneously hypertensive rat

(Spine title: Sympathetic Control of Vascular Stiffening in SHR)

(Thesis format: Integrated-Article)

by

Louis Mattar

Graduate Program in Kinesiology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Louis Mattar 2011

THE UNIVERSITY OF WESTERN ONTARIO
SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES
Certificate of Examination
Supervisor

Examiners

______________________________
Dr. J. Kevin Shoemaker

______________________________
Dr. Rob Petrella

Supervisory Committee

______________________________
Dr. Chris Ellis

______________________________
Dr. Dwayne N. Jackson

______________________________
Dr. Dwayne Jackson

______________________________
Dr. Robert Gros

______________________________
Dr. Phillip Clifford

The thesis by

Louis Mattar
entitled:
On the early onset of vascular stiffening and sexual dimorphism of sympathetic
control in the spontaneously hypertensive rat
is accepted in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy

Date__________________________

_______________________________
Chair of the Thesis Examination Board

ii

Abstract and Keywords
The purpose of this thesis was to explore the role of the sympathetic nervous
system (SNS) in hindlimb vasomotor control during the development of hypertension
(HT). Using an animal model of essential HT (the spontaneously hypertensive rat [SHR])
we demonstrated that neuropeptide Y (NPY) and the Y1 receptor (Y1R) play a greater
role in modulating hindlimb hemodynamics in the early stages of HT compared to
normotensive controls (Wistar Kyoto [WKY]). Hindlimb vascular mechanics
(compliance [C] and viscoelasticity [K]) were assessed using a modified Windkessel
model developed in our laboratory. The hindlimb mechanics did not appear to be
regulated by NPY or the Y1R specifically, but the SNS did appear to regulate the
hindlimb mechanics in both SHRs and WKY animals. The use of female animals in
physiologic research is limited, thus the role of the SNS in developing HT in females is
unknown. Finally, differences in the hemodynamic and hindlimb vascular mechanics
between male and female animals were examined. Female animals exhibited augmented
MAP and HR relative to males in conjunction with greater stiffness and viscoelasticity in
both SHR and WKY animals. Female SHRs also appeared to lose SNS control over the
stiffness and viscoelastic properties of the hindlimb vascular bed, while male SHRs
maintained this control. These sexually dimorphic characteristics provide evidence for a
novel proposed mechanism of cardiovascular regulation in young female rats.
Keywords: Compliance, Conductance, Hexamethonium Bromide, Modified Windkessel
Model, Pulse Wave Velocity, Resistance, Sexual Dimorphism, Spontaneously
Hypertensive Rats, Viscoelasticity, Wistar-Kyoto Rats
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Epigraph

‘I love fools’ experiments. I am always making them.’
Charles Darwin
(1809 ‒ 1882)

‘It is not the mountain we conquer but ourselves.’
Sir Edmund Hillary
(1919 – 2008)
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Chapter 1 ‒ Review of the Literature
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1.1

Introduction
The mechanisms governing the distribution of blood flow throughout the body are

numerous and complex. The methods utilized for blood flow distribution include shortterm (e.g., beat-to-beat) fluctuations in heart rate and cardiac contractility, to more
continuous changes in the diameter of blood vessels and, in some cases, morphologic
changes in the mechanics and structure of vascular tissue. In most cases the sympathetic
nervous system (SNS) is essential in regulating these processes.
Hypertension (HT) is a chronic medical condition that is pervasive in many
industrialized nations (145). The complex etiology of the condition makes it difficult to
manage with medications, and chronic HT is an independent risk factor for many
cardiovascular diseases including myocardial infarction, atherosclerosis, and stroke (13;
58; 136; 156). Hypertension has also been implicated in other pathological conditions
such as metabolic syndrome (11; 79). The physiologic mechanisms contributing to HT
are numerous, and an important role for the SNS is clear; however, the reasons why the
SNS, and other systems, propagate HT remain unclear.
This thesis focuses on the integration of the nervous and cardiovascular systems
and how the two are regulated in normotensive and hypertensive rats. It is important to
note that most of the comparisons made here have been done in very young animals (7
weeks of age). This is a critical point to emphasize, as it exposes differences in
neurovascular coupling as the HT is developing (91; 132). Much of the work describing
alterations in HT has been done in established HT; when the blood pressure has been
elevated for a time. Examining differences in neurovascular regulation as HT develops
may expose novel mechanisms which act to augment the blood pressure. Emphasis will
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be placed on the mechanical properties of the vasculature in normotension and
developing HT, and sex differences in neurovascular regulation of both normotensive and
hypertensive animals will be examined.

1.2

Outline of Thesis
This thesis outlines our attempts to understand the integration of the sympathetic

nervous system (SNS) and cardiovascular systems in the early stages of hypertension
(HT). The experiments outlined were designed to examine the working hypothesis that
the sympathetically-mediated mechanical and biochemical properties of the vasculature
would be altered very early in the development of HT, with specific changes in
neuropeptide Y (NPY) signaling through the Y1 receptor (Y1R). It has been demonstrated
that although female rats possess NPY and the Y1R, this pathway is not utilized in the
control of hindlimb hemodynamics such as it is in male animals (74; 75). Therefore, it
was hypothesized further that alterations in sympathetic control in female hypertensive
rats would be different than those observed in males. To address these hypotheses, the
integration of the SNS and cardiovascular systems was examined by combining
physiological data in the form of systemic and regional hemodynamics, molecular
markers of sympathetic signaling, and mathematical modeling of the mechanical
properties of the hindlimb. This section outlines the rationale for each of the subsequent
chapters, and, hopefully, bridges them creating a more cohesive document.
Chapter 2 entitled “Enhanced regulation of hindlimb vascular control by
neuropeptide Y during the development of hypertension” was designed to assess the role
of the SNS in the hemodynamic responses of exogenous adrenergic receptor (α-AR) and
Y1R agonists in 3-7 week old male SHR animals and WKY controls. It was
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hypothesized that altered neurovascular regulation would occur early in the development
of HT with changes that include modifications to the Y1R and/or α-AR regulation. If so,
then any differences observed in SHR animals in the response to exogenous sympathetic
agonists would reflect alterations to the cellular signaling which might contribute to the
development of HT.
Chapter 3 entitled “Y1 receptor versus sympathetic control of hindlimb vascular
stiffness in spontaneously hypertensive rats” utilized a modeling approach to quantify the
mechanical properties of the vasculature in both normotension and hypertension. We
employed this technique to supplement data from chapter 2 in order to examine the role
of the Y1R in particular, and the SNS in general, in mediating vascular stiffness in HT.
We tested the specific hypothesis that Y1R activation, and the general hypothesis that
sympathetic activation, would contribute to vascular stiffness in the developmental stages
of HT. Should the SNS regulate the stiffness of the vasculature, increased stiffness would
augment blood pressure and exacerbate HT. Increased vascular stiffness is a hallmark of
established HT (81); however, whether the stiffness contributes to, or is a consequence
of, HT is debated (65). Examining the mechanical properties of the vasculature during the
early stages of HT should provide a more complete understanding of the role of vascular
mechanics in augmenting blood pressure.
Sex-based differences exist in sympathetic cardiovascular regulation (74-76) and
the prevalence and severity of HT (5; 67). Chapter 4, entitled “Sympathetic contribution
to peripheral vascular stiffness in young female spontaneously hypertensive rats”, was
designed to examine the role of the SNS in regulating the mechanical properties of the
hindlimb in female animals. Detailed examinations of specific agonist/antagonist control
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were not performed as previous research indicates females do not utilize the NPY system
in vascular regulation (74; 75), and chapter 3 suggests that the regulation of the
mechanical properties are not under Y1R control but, rather, are related to sympathetic
neural activity per se. Therefore, we tested the hypothesis that vascular stiffness and
viscoelasticity are under neurogenic control in females as they appear to be in males. But,
because females appear to rely on different mechanisms of cardiovascular control,
differences in HT would be manifest in the mechanical properties of the vasculature.
Finally, chapter 5 “Evidence for sexual dimorphism in sympathetic control of
vascular function” explores the sex-associated differences observed in hemodynamic and
hindlimb vascular mechanics in both normotensive and hypertensive rats. These
differences were evident during data analysis and warrant some discussion. This chapter
also hypothesizes a mechanism as to why these differences may exist.
The dissertation concludes in chapter 6 with a general discussion about the
implications for the body of work as a whole. The role of NPY and the SNS in
cardiovascular regulation are highlighted, as are the differences in cardiovascular control
between male and female animals. Limitations of the research are addressed, and areas
where this line of research can be continued are proposed.
This dissertation embodies a series of studies which examine the mechanical
and/or biochemical alterations that occur in the early stages of HT. The role of the SNS in
general, and NPY in particular, are investigated as is the role of sex in moderating
differences observed.
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1.3

Mechanisms of Sympathetic Control
The SNS relies on three chemical transmitters to communicate with peripheral

tissues. Adenosine triphosphate (ATP), norepinephrine (NE) and neuropeptide Y (NPY)
are synthesized, stored and released from neurons of the SNS and act via specific
receptors to elicit discrete responses. Of the sympathetic neurotransmitters, NE has
received the most consideration, but a role for NPY in baseline vasomotor control has
emerged (74-76). ATP, NE and NPY exert both acute and chronic effects on the
vasculature. Acutely, all three transmitters elicit vasoconstriction of vascular smooth
muscle cells (VSMCs), which acts to increase vascular resistance (18; 103; 179).
Chronically, these molecules are mitogenic and stimulate VSMCs growth and
proliferation also known as vascular remodeling (121; 170; 176). Vascular remodeling is
a characteristic of HT, typically seen as a thickening and stiffening of the vascular wall
(see below) (34; 48; 104).
The SNS regulates the distribution of blood throughout the body by acting on a
level of the vasculature known collectively as resistance vessels. By altering the diameter
of the resistance vessels the SNS increases the resistance to flow, and therefore limits
tissue perfusion (118). Tissues that require an increase in blood flow, due to increased
metabolic demand, release a host of metabolic vasodilators that compete with, or directly
inhibit, the constrictor effect of the SNS (60; 83).
ATP, a purine nucleotide primarily known for its role as a co-enzyme, fueling
metabolic processes through the cleavage of its high energy phosphate bonds (84), is
released from synaptic vesicles with NE and NPY and is responsible for excitatory
junction potentials (EJPs). EJPs are minute depolarizations that occur in a postjunctional
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cell (often VSMCs) following a single ‘pulse’ from a prejunctional neuron. These EJPs
are rapid and can summate to initiate a mechanical contraction. However, EJPs are rapid
and transient, and are often followed by a slow depolarization that is mediated by NE
((144) see below). ATP acts through two types of receptors (P2X1-7 and P2Y1, 2, 4, 6, 11, 12,
13,14).

P2X receptors are fast inotropic ligand-gated ion channels, and P2Y receptors are

part of the G protein-coupled receptor (GPCR) superfamily, which are described below.
P2X receptors are found on neurons and smooth muscle cells; while, P2Y receptors can
be found on most cells in the body (21; 22).
The archetypal neurotransmitter of the SNS is NE. NE is a catecholamine that is
synthesized from the amino acid tyrosine through a series of enzymatic reactions. NE is
released from sympathetic varicosities in a Ca2+ dependent manner following the
depolarization of the membrane by an action potential. NE exerts its actions on post
synaptic cells through α- and β-adrenergic receptors (AR) (52). There are two types of αARs; α1- and α2-ARs. α1-ARs are primarily found on VSMCs and elicit cellular
contraction (tissue vasoconstriction) through a GPCR mechanism. α2-AR are found
primarily pre-junctionally on nerve terminals, where they inhibit vesicle release through a
negative feedback mechanism. Post-junctionally α2-ARs signal vasoconstriction (53).
While three β-ARs have been identified, cloned and classified as GPCRs (97), the
majority of NEs effect in the vascular system is done through the β2-AR. Stimulation of
the β2-ARs, which are primarily found in arterioles of skeletal muscle, will result in
vasodilation (14). It should be noted, that the β1-AR is found in the heart, and increases
heart rate and contractility. While these inotropic and chronotropic effects will factor into
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vascular regulation, it is the direct role of the α1-AR on the diameter of the blood vessels
supplying a vascular bed that is the primary determinant of tissue perfusion (148).
NPY exerts it actions through a family of GPCRs called Y-receptors. Six
members of the Y-receptor family have been cloned or postulated; however, the
dominant receptors mediating cardiovascular responses are the Y1 and Y2 receptors (Y1R
and Y2R, respectively) (3; 66; 120). The Y1R is primarily found on VSMCs and
preferentially binds NPY (30; 107; 183) eliciting vasoconstriction, potentiation of NE,
and mitogenesis (2; 76; 105; 181). Y2Rs are found in abundance on sympathetic and
parasympathetic nerve terminals (146; 157) and preferentially bind an enzymatically
truncated NPY molecule. NPY is degraded by aminopeptidase P (APP) and dipeptidyl
peptidase IV (DPP IV) in the neurovascular cleft to produce the biologically active NPY336

and NPY2-36, respectively, both of which act via the Y2R to reduce vesicular release in

a negative feedback manner (3; 120; 124; 125).
Many of the vascular receptors mentioned above are classified as G-protein
coupled receptors, or GPCR. GPCR are members of the rhodopsin-like superfamily of
receptors characterized by a 7-transmembrane receptor linked to a guanine nucleotidebinding protein (G-protein) (101). The G-protein is comprised of α-, β-, and γ-subunits
each of which have isoforms resulting in immense diversity (20; 45). Ligand specificity
occurs at the 7-transmembrane receptor domain where activation (from ligand binding)
produces a conformational change in the Gα-subunit resulting in the substitution of a
guanosine diphosphate (GDP) molecule for guanosine triphosphate (GTP). GTP binding
releases the tightly associated Gβ- and Gγ-subunits (the βγ-complex) allowing both the
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Gα-subunit and the βγ-complex to activate targets, thus commencing intracellular
signaling (59; 78).
GPCRs are classified by the actions of the Gα-subunit; however, signaling by the
βγ-complex is now accepted (129). Four main classes of Gα-subunits have been
identified. They include, Gαs which stimulates Adenylyl Cyclase (AC), Gαi which
inhibits AC, Gαq which increases the activity of phospholipase C (PLC), and Gα12/13
which activates the Rho Family of GTP-ases (101; 129).
α1-ARs and some P2Y (P2Y1, 2, 4, 6, 11 and 14) receptors contain Gαq-subunits
culminating in the activation of PLC. PLC enzymatically cleaves the phospholipid
phosphatydlinositol 4,5-bisphosphate (PIP2) into the biologically active diacyl glycerol
(DAG) and inositol 1,4,5-triphosphate (IP3) (114). IP3 binds to the InsP3-receptor on the
sarcoplamsic reticulum resulting in the mobilization of Ca2+ (53). DAG, in turn, activates
Protein Kinase C (PKC) which, in VSMCs, leads to the phosphorylation of myosin light
chain phosphatase (MLCP). Phosphorylation of MLCP reduces its activity, resulting in
sustained Ca2+ sensitization of myosin light chain 20 (MLC20). The sustained Ca2+
sensitization of MLC20 allows for continued actomyosin coupling, and in conjunction
with increased Ca2+ mobilization (from IP3), leads to cellular contraction.
α2-AR’s, some P2Y (P2Y4, 12, 13) receptors and all Y-receptors contain the Gαisubunit. The β-ARs contain Gαs, which acts in opposition to Gαi. Gαs activates AC (26)
which converts ATP into cyclic-adenosine monophosphate (cAMP). Increases in the
concentration of cAMP activate cAMP-dependent protein kinase (protein kinase A;
PKA). PKA phosphorylates a myriad of cellular targets including the sarco/endoplasmic
reticulum Ca2+ ATP-ase (SERCA) and myosin light chain kinase (MLCK). Activation of
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SERCA reduces intracellular Ca2+, while phosphorylation of MLCK reduced its activity
allowing MLCP to reduce the affinity of MLC20 for Ca2+. Both of these events will lead
to reduced actomyosin coupling and relaxation of VSMCs. Inhibition of AC (by Gαi)
prevents the activation of PKA, ultimately leading to increased intracellular Ca2+
concentrations and contraction of VSMCs (2; 20; 86; 115).
The cellular pathways outlined above are required to elicit acute sympathetically
mediated vasoconstriction in blood vessels. Other more chronic sympathetically mediated
GPCR actions have been identified (40; 41). Both NE and NPY have been shown to
activate a variety of mitogen activated protein kinases (MAPKs) which play an important
role in mitogenesis, proliferation and migration of VSMCs (40; 87; 116; 120; 127; 134;
170; 170; 183). Because the targets of second messenger cascades are numerous, cross
talk between many GPCRs signaling cascades occurs, and in many cases leads to the
activation of various MAPK pathways including extracellular signal-regulated kinases
(ERK) 1 and 2 (ERK1/2), p38, and c-Jun N-terminal kinases (JNK) (12; 41; 128; 177).
These pathways lead to gene transcription, cellular proliferation and ultimately vascular
remodeling (see below).

1.4

The Sympathetic Nervous System and Hypertension
Hypertension is a multi-faceted condition that has many complex and diverse

etiologies. Heightened SNS activity is a prominent feature of HT (25; 104; 139; 178) that
begins early in life (24; 48; 169). The underlying cause of augmented SNS activation
leading to HT remains unknown (54); however, the mechanisms involved include
defective baroreceptor autoregulation, increased hypothalamic response to environmental
stimuli, stimulation of renal afferent sympathetics, and elevated thoracolumbar
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sympathetic activity (79). Regardless of the cause, the heightened SNS activity produces
chronically elevated vascular resistance (R) (10; 71; 132) and exposes the vasculature to
trophic factors which can cause inappropriate tissue remodeling (10; 168). This thesis
examines the impact of heightened SNS activity on vascular structure and function as a
critical feature in the early stages of HT.
Detailed examinations of the hemodynamic and phenotypic alterations during the
development of HT have been made (4; 122). Use of the spontaneously hypertensive rat
(SHR) has identified many underlying pathologies that lead to the development of HT,
including alterations in the Renin-Angiotensin System, renal physiology and the SNS
(110; 155; 156). HT develops early in the life of SHR animals (approximately 5-weeks of
age) and elevated sympathetic outflow has been implicated in this early pathology. In the
SHR model, sympathetic innervation of several vascular beds occurs very soon after
birth, before the development of hypertension (64) and neonatal sympathectomy
consistently prevents the development of high blood pressure in SHR (90; 153). Thus,
pre-hypertensive SHR animals at age 4-5 weeks have higher interstitial NE levels in
muscle and fat than their age-matched Wistar-Kyoto (WKY) controls (24). However,
evidence suggests that this innervation pattern is tissue-specific with little difference in
the sympathetic activation of the heart in young SHR and WKY animals (64).
Similarly, evidence indicates that hindlimb vascular remodeling occurs as early as
4-5 weeks of age in the SHR, and may precede the blood pressure augmentation (85; 132;
140). This remodeling displayed regional specificity and debate exists as to the specific
involvement of sympathetic stimuli (91; 140). Furthermore, these studies do not address
the role of NPY in mediating the vascular remodeling associated with HT at this young
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age. Indeed, the roles that NPY plays in the regulation of blood pressure, vasomotor
control and/or vascular mechanics at this critical age are not well understood.

1.5

Signaling Alterations in Hypertension
As mentioned, sympathetic hyperactivity is seen regularly in HT (25; 104; 139;

178). The influence of augmented innervation can be compounded by genetic
modifications which have been identified in HT (33; 44; 56; 143). These genetic
modifications lead to an imbalance between constrictor and dilatory signals, and lead to
increased constriction, augmented vascular resistance and arterial pressure (45; 46; 56;
143).
An extremely important step in GPCR signaling is the process of desensitization.
Desensitization is the mechanism whereby a signaling ‘memory’ is formed (20). If, for
instance, a cell is exposed to NE, GPCR activation and 2nd messenger cascades are
initiated (as outlined above). In addition to the target molecules which regulate
vasoconstriction, another a group of molecules termed GPCR kinases (GRKs), are
activated which lead to the phosphorylation of the GPCR. A phosphorylated GPCR is
targeted by β-Arrestin molecules which internalize the GPCR. If the cell is repeatedly
exposed to a ligand, desensitization is a means by which the cell expresses fewer
receptors (of that specific ligand). Alternatively, the same mechanism allows a cell to
express more receptor when low levels of a specific ligand are present (i.e. sensitization)
(49; 92). A variety of alterations in GRK activity/expression have been associated with
HT (46; 142). For example, increased expression of GRK2 is often seen in hypertensive
models. Increased GRK2 leads to increased desensitization of the β2-AR resulting in
reduced vasodilation, blunted AC coupling and vascular remodeling (36; 61).
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Additionally, transgenic mice expressing a GRK4 gene isolated from human hypertensive
patients demonstrated alterations in dopamine stimulated sodium excretion from the
kidneys, impairments in GRK4 activity and HT (43).
Genetic alterations in HT have also been observed in the β2-AR (44; 45). The
primary role of the β2-AR on VSMCs is vasodilation, mediated by Gαs and the activation
of AC. A number of single nucleotide polymorphisms (SNPs) of the β-AR are associated
with HT. Both the Arg16Gly and Gln27Glu SNPs have little effect on receptor binding
affinity or AC activation, but prevent receptor desensitization compared with wildtype
receptors (17; 55). Additionally, the Thr164Ile SNP results in reduced AC activity and
impaired Gαs coupling (16). Ultimately, the physiological consequence of these SNPs is a
blunted vasodilatory response in VSMCs.
Another type of molecular alteration that occurs in HT is known as signal
switching (33). The β2-AR typically couples with the Gαs subunit (as described above) to
elicit vasodilation. In some cases the β2-AR has been shown to couple to Gαi leading to
MAPK activation (89; 171). The mechanisms that result in signal switching may not be
pathophysiological, but could be a secondary signaling mode of the β2-AR. If this is the
case, it underscores our limited understanding of the molecular mechanisms of cellular
regulation (143).

1.6

Vascular Mechanics
The control of blood flow distribution and blood pressure maintenance in the

body has many levels of regulation. At the systemic level the SNS plays a vital role in
distributing blood away from areas of low metabolic demand, while local metabolic
factors allow for increased blood supply to places where demand is high (7; 31; 113;
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151). The large elastic arteries in the trunk of the body branch and become muscular
resistance vessels in the limbs and visceral organs. Distribution of blood flow is primarily
done through manipulation of the resistance in the vessels feeding a given tissue.
Resistance to flow is determined by the pressure change across a vascular bed and the
flow entering the system (117). The relationships between flow, pressure gradients and
the dimensions of a capillary tube were first established by Jean Leonard Poiseuille (1797
– 1869). Poiseuille’s equation (126) relates a pressure gradient across a tube with the
flow, viscosity of the fluid, length and radius of the tube:
Equation 1.1
where Q is the volume flow per unit time, r is the internal radius , P1 – P2 is the pressure
drop, µ is the viscosity of the blood, and L is the length of the of the tube.
To use Poiseuille’s equation, knowledge of the architecture of the vessels is
needed. This is not always possible to ascertain; however, when considering the vascular
system as a whole, or one of its regions, the formula can be simplified to relate the
pressure difference (i.e. arterial ‒ venous pressure) as the product of the flow (Q; i.e.
cardiac output) and the resistance to flow (R) (117). As the pressure in the venous system
is sufficiently low, R can be calculated as:
Equation 1.2
where R is the resistance, MAP is the mean arterial pressure and Q is the flow (cardiac
output systemically, or volume flow in a large peripheral artery). Notice that an increase
in resistance will cause a drop in flow (if pressure is held constant). In the vascular
system, the most effective way to change the resistance of a vessel is through the
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manipulation of the vessel diameter. Poiseuille’s equation dictates that flow (Q) is
proportional to the radius (r) to the 4th power, so a small change in the diameter of a
vessel will have profound effects on flow through that vessel.
A number of assumptions must be made in order to use Poiseuille’s equation in
physiologic situations so that flow, pressure and/or resistance can be derived from the
equations outlined. These assumptions relate to the properties of the blood, blood flow
and the ‘tube’ in which the flow is traveling. First, it is assumed that the fluid is
homogeneous and its viscosity is the same at all rates of shear. Blood is, of course,
composed of particulate matter (cells) suspended in a fluid (plasma). In arteries where the
radius is sufficiently large compared to the size of red cells, blood behaves as a
Newtonian fluid, and this assumption holds true. However, these fluid characteristics
change as the vessels become smaller at the arteriolar level. The second assumption is
that the liquid does not slip at the wall. This is universally true for liquids, as the friction
between the wall and the flowing liquid makes the velocity at the wall zero. Assumption
three dictates that the flow is laminar with the liquid moving parallel to the wall of the
tube. This assumption is not satisfied in some large vessels where turbulent flow is
possible (i.e. the aorta). Assumption four is also invalid in large arteries, because the flow
is not ‘steady’ but is pulsatile and is subject to acceleration and deceleration. The final
two assumptions deal with the tube in which the flow is occurring. Assumption five states
that the tube is long compared with the region being studied. This is required to allow for
laminar flow to develop (assumption three). The final assumption dictates that the tube is
rigid and the diameter does not vary with internal pressure. Blood vessels are viscoelastic
structures which distend with an increase in arterial pressure during each heart beat.
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Some have argued that in many vascular beds the walls are muscular and blood flow is
sufficiently steady so that the internal diameter does not distend and the application of
Poiseuille’s equation is permitted (118). This speculation may apply to microvascular
beds. Yet, the pulsatile mechanics of microvascular beds have not been studied,
particularly in the context of hypertension. Our laboratory has developed methods to
study the oscillatory stiffness, viscoelasticity and inertial elements of flow in a vascular
bed (172-175) and these methods will be used, for the first time, in a rodent model of
hypertension in the ensuing studies.
The assumptions underlying Poiseuille only allow us to approximate the
physiology of the circulation. Historically, R has been the primary indicator of vascular
regulation, as a change in resistance is indicative of vessel caliber (23; 135). This
however, is an estimate at best, as R only reflects the steady state component of blood
flow and neglects the pulsatile nature of blood flow which violates the assumptions listed
above. The analogue of R in a pulsatile system is termed impedance (Z) and is given by
(173; 174):
Equation 1.3
where R is resistance, i = √ 1, ω is the frequency of oscillation and C is the compliance
of the vessel given by:
∆
∆ ∆

Equation 1.4

where ΔV is a change in volume and Δ(ΔP) is a change in the pressure gradient.
Compliance reflects the change in the pressure difference needed to change the volume of
a system. Increases in C allow for greater volume changes for a given change in the
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pressure gradient (173). C is the inverse of stiffness, and in many disease states, stiffness
is used as a clinical marker of disease severity (i.e. pulse wave velocity) (112; 137).
To better understand the oscillatory nature of the vascular system it is typically
modeled as a Windkessel. Windkessel in German means ‘air chamber’ but in respect to
the vascular system it implies the elastic reservoir created by the aorta and other large
elastic arteries with increasing pressure from each heart beat. The principle of the
Windkessel effect is simply the stretching of the walls of large elastic arteries due to the
ejection of blood from the heart. The stretch of the vessel walls store potential energy
during systole, allowing for a passive recoil of the elastic lamella of the tunica media
creating blood flow during diastole (when the heart is relaxed) (108; 118).
Windkessel models are typically lumped models of the vasculature. Lumped
models are useful tools for studying the vasculature because vascular networks are
immensely complex. By representing the entire structure of a vascular network as a single
tube with the properties of the network as a whole, a “black-box” is created, where the
relationship between inputs and output is easily understood (173). To adequately model
the pulsatile nature of skeletal muscle blood flow, it is necessary to include additional
parameters to Equation 1.3. Equation 1.5 incorporates Equation 1.3 with the addition of
the viscoelastic properties of the vessel (K), and the inductance (L), representing the
effects of fluid and vessel wall inertia, both of which are required in series with C (Figure
1.1) (174):
Equation 1.5
This model (termed the ‘RCKL’ model) uses measured pressure and flow waveforms
(Figure 1.2) which are decomposed and averaged into pressure (P; Figure 1.3), and flow
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harmonics (Q; Figure 1.4) using fast Fourier transformations (15; 158), which can be
used in Equation 1.6 to calculate impedance:
Equation 1.6
This is analogous to Equation 1.2 and when combined with Equation 1.5 we are able to
approximate Q using the measured pressure waveform (Figure 1.3) and Equation 1.7:
Equation 1.7
RCKL predicts a flow waveform based on the measured pressure waveform. By
manipulating the parameters C, K, and L, the calculated flow waveform can be compared
to a measured flow waveform. When congruency between the measured and calculated
waveforms is found, the values for C, K, and L represent the properties of the lumped
vascular bed (Figure 1.5).
The lumped properties obtained using the RCKL model, while providing useful
information about the mechanical properties of a given vascular bed, do have inherent
limitations which need to be addressed. Primarily, because these properties represent the
vasculature as a whole, we are unable to ascribe a specific level of the vascular tree to a
given component of the model (174). Additionally, a large proportion of the resistance in
the model is generated by resistance arterioles, but it is unclear from the model whether
or by how much these vessels also contribute to the compliance of the vascular bed. The
model as it is applied in this thesis only reflects the pressure-flow relationships of the rat
hindlimb being studied, and do not reflect the vasculature as a whole. Further, as surgical
interventions were required to obtain the pressure and flow measurements used, the effect
of anaesthesia and/or the surgery itself in altering the mechanical properties of the
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vasculature cannot be ruled out. Finally, the four components of this model; resistance,
compliance, viscoelasticity and inertia, represent an over simplification of a complex
physiologic system giving us a method to conceptualize the mechanical properties (174).
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Figure 1.1 – Representation of the RCKL model. Resistance (R) in this lumped modified
Windkessel model is in parallel with compliance (C), the viscoelastic properties of the
vessel wall (K), and inductance (L) representing the inertial effects of the blood and
vessel walls.
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Figure 1.2 – Data selection used to estimate the mechanical properties of the vasculature
of the rat hindlimb. ECG (top) arterial blood pressure (middle) and arterial blood flow
(bottom) are obtained during a representative period of baseline or during a reflex
maneuver.
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Figure 1.3 – Averaged pressure waveform from data selection in Figure 1.2. Waveforms
are averaged in both the time and frequency domain to obtain an average pressure
waveform.
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Figure 1.4 ‒ Averaged flow waveform from data selection in Figure 1.2. Waveforms are
averaged in both the time and frequency domain to obtain an average flow waveform.
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Figure 1.5 – Measured (solid) and calculated (dashed) flow waveform from the RCKL
model. The value for resistance (R) is calculated as the mean pressure divided by the
mean flow. The values for compliance (C), viscoelasticity (K), and inertia (L) shown are
those that produced the best agreement between the averaged pressure (Figure 1.3) and
flow (Figure 1.4) waveforms. These values represent the lumped properties of a vascular
bed. ‘E’ as outlined above represents the error (least square difference) between the
measured and calculated waveforms.
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1.7

Vascular Remodeling and Mechanical Alterations in Hypertension
Increased blood pressure and SNS activity both contribute to the characteristic

vascular remodeling seen in HT (34; 48; 104; 164). Both hemodynamic forces acting
from within the vessel and extrinsic factors that act on the vessel wall factor into the
remodeling process (180). Debate exists as to whether vascular remodeling occurs before
blood pressure rises, or occurs as a consequence of HT (65). Many factors contribute to
vascular remodeling; however, this section outlines only those aspects which are
mediated by mechanical or sympathetic mechanisms. For detailed reviews of different
aspects of vascular remodeling see (94; 131; 180).
Mechanical stresses have the ability to alter the composition of biological tissues.
Changes in volume, shear stress and stretch have all been documented to alter the
structure of the vessel wall (69). This section will highlight augmented blood pressure
causing an increase the circumferential stress within the wall of the vessel. The increased
wall stress is sensed by vascular cells (likely via integrins linked to cytoskeletal
components (106)), and stimulates a phenotypic change in VSMCs in an attempt to
normalize the wall tension (described below).
The relationship between arterial pressure and the architecture of a blood vessel is
defined by the Law of Laplace (23; 163):
Equation 1.8
where T is the wall tension (wall stress), P is the distending (arterial) pressure, ri is the
internal radius and h is the wall thickness. Using the Law of Laplace we are able to
conceptualize the physiologic mechanisms at work in the vessel wall that act to counter
the increased wall tension created by augmented pressure. Acutely, an increase in
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distending pressure will cause an increase in myogenic constriction, thereby reducing ri
in an attempt to restore the wall stress; but, at the same time increasing vascular
resistance (see Poiseuille’s equation) resulting in a positive-feedback mechanism which
ultimately increases blood pressure (65; 73).
Chronically, vascular tissue remodels as a compensatory mechanism to normalize
wall stress. Hypertrophy and hyperplasia occur in VSMCs following a phenotypic shift
from one of constriction to synthesis. VSMCs begin to divide and excrete extracellular
matrix. The excretion of extracellular matrix proteins alters the proportions of
components of the vessel wall and can perpetuate the remodeling process, as it has been
shown in vitro that VSMCs are sensitive to the makeup of the medium on which they are
grown (68; 116; 152). In this instance, vascular remodeling is a consequence of HT (1;
19).
Extrinsic regulators of vascular remodeling are numerous and include angiotensin
II, nitric oxide, matrix metalloproteinases, inflammatory mediators, sex hormones, and
sympathetic neurotransmitters (2; 40; 50; 131; 147; 167). The vasculature is chronically
exposed to these factors, with the exception of sex hormones which have a more
pronounced role following puberty. The cumulative activation of vascular cells is thought
to initiate vascular remodeling in the absence of augmented blood pressure. As outlined
in Section 1.3 activation of MAPKs can lead to gene transcription, protein translation and
ultimately vascular remodeling. The processes which result in vascular remodeling are
not exclusive to VSMCs, as endothelial cells (ECs) and adventitial fibroblasts (AFB)
express a number of the same receptors as VSMCs. Importantly for the remodeling
process AR and Y-receptors on AFB stimulate cell growth and protein synthesis, further
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altering the makeup of the extracellular matrix and facilitating VSMC activation and
migration (42; 68; 116; 152). The activation of vascular cells can occur independently of
arterial pressure causing a remodeling that occurs before the pressure is augmented (85;
132; 140).
Both of the mechanisms described independently cause vascular remodeling, but
they can also act in conjunction with one another to accelerate the remodeling process.
Thus, the study of vascular remodeling in HT is immensely complex. Multiple processes
converge to elicit the transformation of the vessel wall (65; 133; 180). Compounding the
situation in HT is the continual augmentation of blood pressure, and associated comorbidities. Functionally, it is the narrowing of the lumen of blood vessels and the
thickening of the vessel wall which promote HT. A narrower lumen increases the
resistance to flow thus adding to the increased blood pressure (63; 165). Thickening of
the arterial wall acts to stiffen the vessel which adds to HT by increasing the afterload on
the left ventricle (119). Afterload is dependent on systemic pressure and reflects the force
needed to open the aortic valve. Afterload is augmented by the summation of systolic
pressure (generated by the left ventricle) and pressure waveforms reflected from the
periphery. Reflected pressure waveforms arise from sites of incongruity (i.e. bifurcations)
in the peripheral vasculature. In a healthy arterial system, wave reflections reach the aorta
during diastole which adds little to the workload of the heart (as the aortic valve is
closed). Stiffer blood vessels transmit both outgoing and reflected pressure waveforms
faster, allowing the reflected waveform to return to the aorta during systole and forces the
heart to work harder to expel blood (81; 119; 161; 162).

28
Details of the mechanisms responsible for vascular remodeling are being
elucidated to determine whether augmented pressure leads to vascular remodeling, or the
remodeling initiates the rise in pressure (35; 65; 94; 164). Indeed both scenarios are
evident (63; 70), and likely occur in concert to generate cardiovascular dysfunction.
Clinical assessment of vascular stiffening is typically measured using either pulse wave
velocity, and/or arterial compliance (8; 72). Pulse wave velocity and arterial compliance
are useful tools to assess either ‘central’ or ‘point’ arterial stiffness, respectively, but
neglect the contribution of the microcirculation in mediating stiffness. An emerging
hypothesis suggests that the microvasculature is the site where remodeling begins leading
to changes in central arteries, and ultimately HT or cardiovascular disease (88; 96),
although this has not been established. Thus, the functional and morphologic bases of the
vascular properties in the developmental stages of HT are required. The studies in this
dissertation emphasize vascular remodeling using both functional and morphologic
measurements, with emphasis on peripheral hindlimb vascular beds and systemic
vascular measures that directly relate to stiffness.

1.8

Estrogen, the Vascular System and Hypertension
Estrogens, androgens and progestogens, the sex hormones, are groups of

structurally-related steroid hormones which exert distinct actions throughout the body.
Estrogens have received the most attention in the literature and have been linked to both
beneficial and adverse cardiovascular outcomes (111; 119). Of the three estrogens:
estradiol, esterone, and estriol, estradiol (E2) is the most biologically available and is has
the greatest influence on tissue function and structure (141). This section examines the
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physiologic role of E2 in vascular tissue, and will examine the evidence for and against
protective effects of E2.
A myriad of discrete physiologic effects have been identified for E2 outside of
reproductive tissues. Specifically in vascular tissue (predominantly ECs and VSMCs)
both rapid (acute) and genomic (chronic) effects have been identified and warrant some
discussion (29; 154). Because estrogen is derived from cholesterol, it readily diffuses
through the plasma membrane and can bind to the two related estrogen receptors (ER)
that have been identified and cloned. The ERα and ERβ are members of a nuclear
receptor superfamily of ligand- or hormone-dependent transcription factors. Both
receptors display high homology, similar affinity for E2, and coexpression in many
tissues (32; 109). However, distinct expression patterns have been documented, and
where co-expression exists, ERβ has been suggested to modulate the actions of ERα
(159).
Estradiol exerts a host of acute effects in vascular tissues. These effects occur in
the order of seconds to minutes and are initiated far too quickly to involve gene
transcription (102; 130). These effects were initially attributed to a membrane bound
subpopulation of the ERα (38), but many of the acute responses to E2 have now been
ascribed to a novel GPCR known as GPR30. It should be noted that debate as to whether
GPR30 is in fact an estrogen receptor exists (95; 123). Acutely E2 typically elicits
endothelial dependant vasodilation. The mechanism has been linked to GPR30
stimulation of endothelial nitric oxide synthase (NOS). Additionally, acute activation of
GPR30 by E2 has been linked to activation of PKA, and phosphoinositide 3-kinase (PI3)
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kinase. Concurrent activation of MAPKs, Raf and Src kinases leads to genomic
translation and thereby linking the acute and chronic effects of E2 (47; 102).
As with many GPCRs, 2nd messenger signaling cascades initiated by GPR30 can
activate pathways that promote both constriction and relaxation depending on the cell
type on which they are expressed. For example, E2 stimulated activation of PI3 kinase in
ECs leads to the induction of endothelial NOS which produces the potent vasodilator
nitric oxide. In VSMCs PI3 kinase activation leads to the phosphorylation of MLCK
which promotes constriction (101; 166). Furthermore, both ECs and VSMCs express ERα
and ERβ which, when activated, lead to the transcription of a host of proteins associated
with vascular cell signaling (39). Many of these transcripts confer beneficial phenotypic
alterations in both ECs and VSMCs resulting in reduced leukocyte adhesion, inhibition of
VSMC proliferation, and cell survival (38). On the other hand, HT has been associated
with a genetic variant of the ERβ and it has been clearly documented that E2 taken as an
oral contraceptive augments blood pressure (27; 93; 149). Additionally, the discontinued
use of hormone replacement therapy due to increased risk of cardiovascular disease and
some forms of cancers, shed doubt on the beneficial effects of E2 (9; 82; 98).
Evidence suggests that male and female animals may utilize different strategies to
regulate a variety of processes in the body. From cellular mechanisms responsible for cell
survival (99), to blood pressure regulation by the SNS (57; 62; 138), it appears that
females may rely on different mechanisms to maintain cardiovascular homeostasis. For
example, female rats possess NPY and the Y1R, but unlike males, this pathway
contributes little to baseline blood flow control (74-76). Further, E2 has been shown to
down-regulate NPY mediated control of hindlimb blood flow in females (77).

31
Moreover, in humans, E2 is the leading candidate behind the so-called ‘female
advantage’ in cardiovascular disease (80). The ‘female advantage’ refers to the
epidemiologic observations that prior to menopause, the prevalence and severity of a
number of cardiovascular diseases, including HT, are markedly lower in females than age
matched males. Following menopause, the ‘protection’ is lost, and the rates and severity
of HT and other cardiovascular diseases including atherosclerosis, myocardial infarction
and coronary artery disease (among others), in women surpass those found in age
matched males (Figure 1.6). The differences between males and females in figure 1.6
reflects the prevalence in the population, and while E2 is has been identified as a
contributor to the dimorphism, little is known about the mechanisms responsible.
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Figure 1.6 ‒ Prevalence of high blood pressure in adults age 20 and older, by age and
sex. Rates of hypertension among males are greater than those found in females up until
45years of age, at which point females surpass males in prevalence. Data from (5).
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As mentioned, E2 has the ability to both dilate and constrict blood vessels (101;
166), and can confer both beneficial and adverse effects in systemic vascular regulation
(27; 38; 93; 149). Further, E2 has also been shown to both augment and reduce vascular
stiffness which can have direct effects on blood pressure (37; 51; 100; 150). Additionally,
E2 is known to influence the development of the SNS (6; 28; 182) and can modulate its
activity (160). Therefore the role of E2 in regulating sympathetic cardiovascular control
in both health and disease remains unclear.

1.9

Summary
Hypertension is a multifactorial condition with much pathology. It manifests

clinically as augmented arterial pressure and a clear role for the SNS is evident. The role
of the sympathetic nervous system in established HT has been extensively studied but the
contribution it plays in the early stages of HT is less well understood. Both the regulation
of hemodynamics and the mechanical properties of the vasculature are altered in HT.
This thesis examines the role of NPY in particular, and the SNS in general in regulating
the changes observed in males and contrasts them with observations made in female
animals. Furthermore, the ability of the SNS to regulate vascular mechanics in females is
unknown and the role of the animal’s sex in regulating hemodynamics, vascular
mechanics and sympathetic control in normotension and HT, will be addressed.
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Chapter 2 ‒ Enhanced regulation of hindlimb vascular control by
neuropeptide Y during the development of hypertension
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2.1

Introduction
Hypertension (HT) develops early in the life of the spontaneously hypertensive rat

(SHR; approximately 5-weeks of age). Elevated sympathetic nervous system (SNS)
activity is often observed in the pathology of hypertension (2; 14; 15; 25) and neonatal
sympathectomy consistently prevents the development of high blood pressure in the SHR
(11; 24). Thus, the development of HT is related to sympathetic activation. However, the
role of specific sympathetic neurotransmitters and post-junctional receptor control in the
development of HT remains unclear.
Sympathetic neurotransmitters responsible for vascular control in skeletal muscle
include norepinephrine (NE) and neuropeptide Y (NPY). Acutely, these
neurotransmitters signal vasoconstriction (26) leading to increased peripheral vascular
resistance. Chronically, these same mediators can exert trophic effects (4), which can
lead to inappropriate tissue remodeling with outcomes such as wall thickening, wall
stiffening and lumen narrowing. Of the sympathetic neurotransmitters, NE has received
most attention as an etiology of HT, and evidence is mounting which suggests a role for
NPY in vasomotor control (7; 8) and, in particular, HT (5; 16).
NPY acts via a variety of Y-receptors on vascular smooth muscle cells (VSMC)
to elicit diverse cardiovascular effects (1; 17). A possible role for NPY in the
development of HT was shown by Shin et al. (21) who, in a two-kidney, one-clip
renovascular model of HT, blunted the rise in blood pressure via NPY Y1 receptor (Y1R)
antagonism, a mechanism that was independent of renin release. Thus, it is possible that
NPY exerts an important influence on hindlimb vasomotor control in the developing
stages of HT. The purpose of this experiment was to test the hypothesis that altered
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neurovascular regulation occurs early in the development of HT with changes that
include modifications to Y1R and/or α-adrenergic receptor (AR) regulation. Our approach
was to assess the hindlimb hemodynamic responses of exogenous α-AR and Y1R agonists
in the early stages of HT and to combine these integrated responses with an analysis of
receptor protein expression in young hypertensive (SHR) and normotensive (Wistar
Kyoto; WKY) controls.

2.2

Methods

Experimental Animals
The experimental protocol was approved by the Animal Use Subcommittee at The
University of Western Ontario. Male Wistar Kyoto (WKY) and spontaneously
hypertensive (SHR) rats were grouped according to age with emphasis on 3-5 weeks of
age (SHR, n=10, 108±28 g; WKY, n=11, 89±27 g), 7 weeks of age (SHR, n=16, 199±24
g; WKY, n=17, 195±6 g) and 9 weeks of age (WKY only, n=5, 260±8 g).
Data collection and analysis
Non-invasive blood pressure (NIBP) was measured in a subset of 3-5 (SHR, n=6;
WKY, n=7) and 7 week-old (SHR, n= 8; WKY, n=8) animals with a volume pressure
recording sensor and an occlusion tail-cuff (CODA System, Kent Scientific, Torrington,
CT). Measures of systolic, diastolic, and mean arterial pressures (MAP), as well as heart
rate (HR) were obtained. The animals were familiarized with the protocol prior to data
collection.
All animals underwent an acute in vivo vasomotor control study. Animals were
anesthetized with an intraperitoneal injection of α-chloralose (80 mg/kg) and urethane
(500 mg/kg). This mixture was used to ensure minimal impact on reflex cardiovascular
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control (12; 13). Once surgical depth was achieved, the right jugular vein was cannulated
with PE50 tubing for the administration of a dilute mixture of α-chloralose (8-16
mg/kg/hr) and urethane (50-100 mg/kg/hr) to maintain anesthesia throughout the
protocol. A fluid filled PE50 cannula was inserted into the right common carotid artery to
record arterial blood pressure using a pressure transducer (model MLT844;
ADInstruments Colorado Springs, CO) and the signal was amplified using a bridge
amplifier (model ML118 PowerLab Quad Bridge Amplifier; ADInstruments). HR was
calculated online from the systolic peaks of the pressure signal and was used in
conjunction with blood pressure and temperature (rectally) to ensure that the animal
remained at a stable surgical depth of anaesthesia throughout the experiment. All data
was collected using Chart 5 (ADInstruments) with a sampling rate of 4000Hz.
A midline incision was made to expose the visceral organs which were
repositioned to reveal the bifurcation of the descending aorta into the iliac arteries. The
right iliac artery was cannulated with PE50 tubing inserted rostrally to the bifurcation of
the aorta for the delivery of vasoactive compounds (see below). Femoral blood flow
(QFem) was measured in the intact (left) hindlimb with a Transonic flow probe (0.7 PSB
and model TS420 Perivascular Flowmeter Module; Transonic Systems, Ithaca, NY)
positioned approximately 3mm distal to the femoral triangle. Care was taken to ensure
that nerves and vessels were not damaged during this process. The area was covered with
an innocuous water-based gel.
The animals were allowed to recover from the surgery for 1 hour. Baseline values
were measured over a 10 minute period after which a 160 μL bolus of the agonists
phenelypherine (PE; 2.5 µg/kg) or neuropeptide Y (NPY; 15 µg/kg) were administered to
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all of the animals via the iliac artery. To test the influence of the Y1R in baseline
cardiovascular control, bolus’ of the selective Y1R antagonist N-[(1R)]-4[(Aminoiminomethyl) amino-1-[[[(4-hydroxyphenyl) methyl] amino] carbonyl] butyl-aphenylbenzeneacetamide trifluoroacetate (BIBP3226; 100 µg/kg) were infused into the
hindlimb of a subset of 7-week-old animals (SHR n, = 10; WKY, n = 9). The peak
response to BIBP3226 was measured approximately 10 minutes following the infusion.
The ganglionic antagonist hexamethonium bromide (Hex; 25 mg/kg intravenously) was
infused systemically in all animals to determine the viability of the sympathetic nervous
system in the preparation. The dose of Hex that was used is higher than that of previously
published reports (9; 22), in which 20 mg/kg of intravenous Hex abolished (renal) SNA
in both SHR and WKY animals between 15 and 20 weeks of age. All drugs were
purchased from Sigma-Aldrich (St. Louis, MO) with the exception of BIBP3226 (Tocris
Bioscience; Ellisville, MO).
Changes in femoral vascular conductance (Cond = QFem/MAP x 1000;
µL/min/mmHg) were used as an indicator of vasomotor contractile state. Drug responses
were compared using the 5-second average at the nadir and at 360 seconds post infusion,
and these were compared to a 5-second baseline collected immediately prior to the start
of the infusion. Additionally, the area over the curve (AOC; arbitrary units, A.U.) was
calculated using the trapezoid method (20).
Western blot analysis
Following the infusion protocol, the red portion of the vastus lateralis muscle
from the left hindlimb of 7 week-old animals was extracted and frozen for protein
analysis. Briefly, equal amounts of total protein (60 μg for Y1R and 120 μg for tyrosine
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hydroxylase (TH) and α-AR) were assessed by western blot. Membranes were incubated
overnight in primary antibody specific to either rat, human or mouse anti-Y1R (1:300,
affinity purified rabbit anti-mouse Y1R IgG, Alpha Diagnostic International, Cat. No.
NPY1R11-A, San Antonio, TX, USA), anti-α1-AR (1:400 affinity isolated rabbit, SigmaAldrich Cat. No. A270) or anti-TH (1:1000 purified rabbit polyclonal antibody,
Millipore, Cat. No. AB152, Billerica, MA, USA) in TTBS with 2% non-fat milk.
Membranes were washed 3 times in TTBS then incubated in secondary antibody (goat
anti-rabbit, or anti-mouse; 1:3000) conjugated to horseradish peroxidase (HRP; Bio-Rad,
Cat. No. 170-6518) and Precision Protein StrepTactin-HRP Conjugate (1:10000; BioRad, Cat.No. 161-0380) in TTBS with 2% non-fat milk for 1 hour and developed using
Immun-Star WesternC chemiluminescent (Bio-Rad, Cat. No. 170-5070) and detected
using a Bio-Rad ChemiDoc XRS system (Bio-Rad, Cat. No. 170-8070) with a
supersensitive 16-bit CCD. Images were analyzed using Quantity One 1-D Analysis
Software (Bio-Rad, Cat. No. 170-9600).
Statistics
The effect of age and strain on the progression of hypertension (NIBP measures)
was assessed with a mixed two-way ANOVA (Statistical Analysis System (SAS) 9.1,
SAS Institute Inc., Cary, NC, USA). The effects of group and the infused vasoactive
agonists were assessed by the AOC as well as the difference from baseline at the nadir
and 360 seconds post infusion using a mixed two-way ANOVA, again, on age and strain.
The hemodynamic response to BIBP3226 infusion was compared to baseline using a
paired Student’s t-test within a strain (SigmaStat 3, Systat Software Inc., San Jose,
California, USA). Western blot data were compared between strains of the 7 week-old
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animals using an equal variance Student’s t-test (SigmaStat 3). Differences were
considered significant at P<0.05 and Tukey’s post hoc analysis was used to identify
where differences occurred in the ANOVAs. Data are represented as mean ± standard
deviation.

2.3

Results

Non-invasive blood pressure
As expected, SHRs had higher arterial pressure as measured by NIBP versus
WKYs (Table 2.1). Additionally, 7 week-old animals (of both strains) had higher
pressure than 3-5 week-olds. Anesthetic administration dropped blood pressure, however,
data from our lab indicates that reflex cardiovascular control using this anesthetic is
maintained (Usselman et al., In Press)
In Vivo vasomotor control study
Hemodynamic values during baseline and following Hex administration can be
found in Table 2.1. Table 2.2 depicts the hemodynamics following bolus infusions of
both PE and NPY. Figure 2.2 shows the change in Cond in response to PE in 3-5 week
and 7 week-old SHR and WKY animals (Figure 2.2; top and bottom respectively). In
response to PE infusion, Cond in 3-5 week-old WKY animals fell by 2.8±2.9
µL/min/mmHg (P<0.05 versus baseline) and returned to baseline by 360s (not significant
(N.S.) versus baseline). The femoral vascular conductance of 3-5 week-old SHR animals
fell by 2.9±2.8 µL/min/mmHg (P<0.05 versus baseline) in response to PE and returned
to baseline at 360s (N.S. versus baseline). In 7 week-old WKY animals, PE did not
significantly reduce Cond (N.S.) but in 7 week-old SHR animals Cond fell by 8.1±6.3
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µL/min/mmHg (P<0.05 versus baseline) and remained depressed past 360s (4.7±3.4
µL/min/mmHg; P<0.05 versus baseline).
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Figure 2.1 ‒ Representative raw data tracings from 7 week old spontaneously
hypertensive (SHR) and Wistar-Kyoto (WKY) rats in response to both neuropeptide Y
(NPY; 15μg/kg) and phenylephrine (PE; 2.5μg/kg). Solid line represents the start of drug
infusion (0 seconds) and dashed line represents 360 seconds post infusion.

Table 2.1 ‒ Non-invasive blood pressure and in vivo hemodynamic variables at baseline and following ganglionic blockade.
NIBP

Anesthetized Baseline

Hexamethonium (25mg/kg)

Age

MAP

MAP

HR

QFem

Cond

MAP

HR

QFem

Cond

Group

(mmHg)

(mmHg)

(BPM)

(mL/min)

(µL/min/mmHg)

(mmHg)

(BPM)

(mL/min)

(µL/min/mmHg)

3-5

102±21

68±12

391±52

0.49±0.35

7.5±6.2

59±6*

355±25

0.80±0.18*

13.6±2.8*

7

128±19‡

72±13

314±73

0.69±0.35

9.9±5.6

67±2

348±51

0.91±0.37*

13.7±5.6*‡

9

--

73±11

300±30‡

0.57±0.32

7.5±3.4

61±4*

365±22*

0.69±0.19

11.2±2.9

3-5

141±20†

89±19†

462±28†

0.57±0.42

6.7±4.7

64±9*

405±24† 0.70±0.15*

11.2±3.2*

7

157±22†

94±21†

377±59‡† 0.97±0.64†

10.2±5.4

79±5*†

372±15‡ 1.06±0.44‡

14.1±6.3†

Strain

WKY

SHR

Values are mean ± standard deviation. Spontaneously hypertensive rat = SHR; Wistar-Kyoto = WKY; non-invasive blood pressure =
NIBP; mean arterial pressure = MAP, heart rate = HR, femoral blood flow = QFem and femoral vascular conductance = Cond. *
denotes P<0.05 versus baseline; † denotes P<0.05 versus age-matched WKY; ‡ denotes P<0.05 versus 3-5 week-old within the same
strain.
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Table 2.2 – Hemodynamic response prior to and following phenylephrine and
neuropeptide Y.

Strain

Age
MAP
(Weeks) (mmHg)

HR
(BPM)

QFem
(mL/min)

Baseline (Prior to Drug Infusion)
SHR(n=10)

3-5

85±17*

460±14*

0.50±0.34

WKY(n=11)

3-5

71±13

369±30

0.47±0.37

SHR(n=8)

7

97±11*

453±8*

1.32±0.51*

WKY(n=8)

7

80±18

351±46

0.68±0.56

PE
SHR

3-5

98±18a

455±16*

0.29±0.22a

WKY

3-5

90±16a

366±22

0.33±0.33a

SHR

7

110±8a

448±8*

0.52±0.12a

WKY

7

99±22a

363±57

0.43±0.49a

NPY
SHR

3-5

104±16a 452±15*

0.33±0.38a

WKY

3-5

95±18a

368±25

0.31±0.26a

SHR

7

120±14a 457±16*

0.34±0.25a

WKY

7

109±10a

0.45±0.55a

332±13

Values are mean ± standard deviation. Spontaneously hypertensive rat = SHR; WistarKyoto = WKY; mean arterial pressure = MAP, heart rate = HR and femoral blood flow =
QFem; PE = phenylephrine (2.5μg/kg); NPY = neuropeptide Y (15μg/kg). * denotes
P<0.05 versus baseline (of same age group). Main effect statistics: a denotes P<0.05
versus baseline.
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Figure 2.2 – The change in hindlimb conductance to phenylephrine (PE; 2.5μg/kg) in 3-5
week-old (top) and 7 week-old (bottom) spontaneously hypertensive (SHR) and Wistar
Kyoto (WKY) rats. Nadir represents the minimum conductance reached and 360
represents 360 seconds post infusion. Values are mean ± standard deviation. * denotes
P<0.05 versus baseline. Refer to Table 2.1 for baseline values.
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Figure 2.3 depicts change in Cond in responses to NPY in both 3-5 and 7 weekold SHR and WKY animals (Figure 2.3; top and bottom respectively). In 3-5 week-old
WKY animals, NPY reduced Cond by 4.0±4.1 µL/min/mmHg (P<0.05 versus baseline)
which returned to baseline by 360s (N.S.). With NPY infusion, femoral vascular
conductance fell in the 3-5 week-old SHR animals by 2.5±2.3 µL/min/mmHg (P<0.05
versus baseline) and returned to baseline by 360s (N.S.). In 7 week-old WKY animals,
Cond was not significantly reduced (N.S. versus baseline), but fell by 5.9±3.4
µL/min/mmHg (P<0.05 versus baseline) in 7 week-old SHR animals and remained
depressed at 360s (2.8±2.7 µL/min/mmHg; P<0.05 versus baseline).
The areas over the curve (AOC) for both NPY and NE in SHR and WKY animals
were not different between either strain or drug at 3-5 week of age (Figure 2.4; top, N.S.).
At 7 weeks of age, the AOC in response to PE was not different between the strains;
however, the response to NPY was greater in SHR animals versus WKY animals (Figure
2.4; bottom; P<0.05 versus WKY in NPY).
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Figure 2.3 ‒ The change in femoral vascular conductance to neuropeptide Y (NPY; 15
μg/kg) in 3-5 week-old (top) and 7 week-old (bottom) spontaneously hypertensive (SHR)
and Wistar Kyoto (WKY) rats. Nadir represents the minimum conductance reached and
360 represents 360 seconds post infusion. Values are mean ± standard deviation. *
denotes P<0.05 versus baseline. Refer to Table 2.1 for baseline values.
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Figure 2.4 ‒ Area over the curve (AOC) of femoral vascular conductance in response to
phenylephrine (PE; 2.5 μg/kg) and neuropeptide Y (NPY; 15 μg/kg) in spontaneously
hypertensive (SHR) and Wistar Kyoto (WKY) rats. Values are mean ± standard
deviation. * denotes P<0.05 versus WKY.
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Figure 2.5 ‒ Representative raw data tracing from 7 week old spontaneously
hypertensive (SHR) and Wistar-Kyoto (WKY) rats in response to BIBP3226 infusion.
BIBP3226 data were taken approximately 10 minutes post infusion. Bar represents 50
seconds.
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Figure 2.6 – Femoral vascular conductance in 7 week-old spontaneously hypertensive
(SHR) and Wistar-Kyoto (WKY) rats at baseline and following BIBP3226 (100µg/kg).
Peak response occurred approximately 10 minutes after infusion. Values are mean ±
standard deviation. * depicts P<0.05 versus SHR baseline.
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In the 7 week-old WKY animals, hindlimb conductance was 9.6±3.9 at baseline
and 12.0±4.4 µL/min/mmHg (N.S. versus baseline) following BIBP3226 infusion.
However, Cond in the 7 week-old SHR animals increased from 9.4±4.3 µL/min/mmHg at
baseline to 15.5±6.5 µL/min/mmHg following BIBP3226 (P<0.05 versus baseline;
Figure 2.6).
Following Hex administration, the hemodynamic responses in the 3-5 week-old
group from both strains were similar whereby MAP decreased, HR decreased and Cond
increased (Table 2.1). However, divergent responses were observed between the SHR
and WKY animals at 7 weeks of age in response to Hex. Most notably, MAP was
reduced in the SHR animals, while no changes were observed in 7 week-old WKY
animals. It is noted here that the fall in MAP with Hex in the SHR group was not
accompanied by a rise in heart rate which stands in contrast to the WKY group which
experienced tachycardia. This observation raised the question as to whether the divergent
responses between strains at 7 weeks were due to animal maturation and not hypertension
per se. To address this question, the Hex approach was repeated in a subset of 9 week-old
WKY animals. In this group ganglionic blockade evoked reductions in MAP and a rise in
HR following Hex (Table 2.1). These responses were closer to those of the 7 week-old
SHR animals than 7 week-old WKY animals.
Western Blot Analysis
Distinct bands of chemiluminescence were observed for the Y1R, α-AR and TH.
The Y1R expression in SHR red vastus was 1.7±0.5 A.U. compared to 1.2±0.6 A.U. in
the WKY animals (P<0.05; Figure 2.7, top). There were no differences between the
strains in either α-AR (Figure 2.7, middle) or TH expression (Figure 2.7, bottom).
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Figure 2.7 ‒ Western blot analysis of the neuropeptide Y (NPY) Y1 Receptor (Y1R; top),
α-adrenergic receptor (α-AR; middle) and tyrosine hydroxylase (TH; bottom) in the red
portion of the vastus lateralis from spontaneously hypertensive (SHR; black bar) and
Wistar-Kyoto (WKY; grey bar) rats. Insert in box - representative western blot for each
protein. Values are mean ± standard deviation.* denotes P<0.05 versus WKY.
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2.4

Discussion
The main finding of the present study is that following a bolus of NPY, but not

PE, 7 week-old SHR animals exhibited greater and prolonged reductions in Cond
compared to age-matched WKY animals. Additionally, 7 week-old SHR animals
displayed a greater dilatory response to Y1R antagonism with BIBP3226 versus WKY
animals, and the expression of the Y1R in skeletal muscle was greater in SHR versus
WKY rats. These data suggest that the involvement of the NPY system in cardiovascular
regulation is upregulated in the early stages of hypertension.
The currently accepted role of the SNS in hypertension is heightened sympathetic
activity leading to increased vascular resistance (3; 10). While it is traditionally thought
that norepinephrine and the α-AR are primarily responsible for these effects (6; 23), the
current data highlight an augmented role for the NPY system in the early stages of the
condition. The divergent responses observed between the strains to the exogenous
agonists (PE and NPY) only emerged at 7 weeks of age. The lack of differentiation
between the strains to either PE or NPY at 3-5 weeks of age indicates that there appears
to be a temporal onset of modified neurovascular coupling. In this context, it appears that
the NPY system develops earlier in SHR animals than in the WKY strain.
Regulation of the NPY system could be altered in a number of ways: 1) enhanced
NPY bioavailability following either increased neurotransmitter release and/or reduced
neurovascular proteolytic breakdown, 2) modified Y1R expression, and/or 3) altered postreceptor regulation of receptor sensitivity or intracellular contractile machinery. Here we
examined the second option with emphasis on adrenergic and NPY-mediated
neurovascular regulation. SHR and WKY animals displayed similar reductions in Cond
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to exogenous PE and showed no difference in the expression of TH, the rate limiting
enzyme in the production of norepinephrine, or in the α-AR expression, the primary
receptor governing the VSMC response to norepinephrine. Therefore, we conclude that
the adrenergic system is not modified between SHR and WKY animals at 7 weeks of age.
In contrast, the increased expression of Y1R in skeletal muscle observed in the SHR
coincided with the heightened or prolonged in vivo responses to Y1R activation or
blockade. These data indicate that the NPY system of 7 week-old SHR animals plays a
larger role in sympathetic control of hindlimb vasculature compared to age matched
WKYs.
The main purpose of the Hex condition was to determine if ganglionic control
over the cardiovascular system was maintained under anaesthesia. To this end, the current
Hex results indicate that residual autonomic control was present whereby ganglionic
blockade produced a reduction in blood pressure in both strains. This hypotensive
response tended to be greater in the SHR (-28 and -16% change from baseline in 3-5 and
7 week old SHRs respectively) than WKY (-14, -6 and -16% change from baseline in 35, 7 and 9 week old WKYs respectively) suggesting a greater role for autonomic
cardiovascular regulation in hypertensive animals. This is consistent with previous
reports (2) of elevated sympathetic activation in SHR. The new observation of this study
was that these differences are evident as early as 7 weeks of age.
However, an unexpected observation of the current study was the age-associated
difference in the response to ganglionic blockade. While determining the mechanistic
detail of neurovascular control in developing HT was not the purpose of the Hex trials,
the observations deserve consideration. In both strains at 3-5 weeks of age, Hex caused
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reductions in MAP and HR. The bradycardia and Hex-induced hypotension suggest
immature reflexive cardiac control in 3-5 week-old animals. This pattern was modified
by 7 weeks of age. The 7 week-old WKY animals demonstrated a smaller hypotensive
response to Hex which was accompanied by the expected tachycardia, both of which
were augmented to statistically significant levels by 9 weeks of age. In contrast, the SHR
animals failed to mount a tachycardic response to Hex despite a marked fall in blood
pressure. To examine whether the altered response to Hex by 7 weeks in SHR versus
WKY animals was simply due to a more rapid maturation of neurovascular coupling in
the SHR strain, a separate group of 9 week-old WKY animals was studied to see if they
would mimic the 7 week-old SHR group. In this group, Hex induced a marked fall in
MAP with the expected increase in HR. Thus, there appears to be important agedependent alterations in neurovascular coupling in both strains, with the potential for
aberrant development in the SHR strain that contributes to hypertension.
The augmented hindlimb vascular conductance to BIBP3226 infusion suggests
the intriguing possibility that the heightened Y1R regulation in 7 week old SHR animals
may contribute to the early stages of HT. This observation is counter to reports from Y1receptor knockout mice (18) or from studies reporting an acute infusion of BIBP3226
does not affect basal blood pressure in normotensive or SHR rats (27). However these
reports were conducted in older animals, and the response here may be specific to the
initial stages of HT. Nonetheless, chronic activation of the Y1R, independent of changes
in blood pressure, is mitogenic resulting in vascular wall thickening and stiffening (19)
which would have a concurrent impact on basal blood pressure and its long-term
regulation.
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2.5

Conclusion
The prolonged reduction in femoral vascular conductance observed in response to

exogenous infusions of NPY in SHR but not WKY support the hypothesis that altered
neurovascular regulation occurs in HT. Specifically, SHR animals appear to emphasize
enhanced Y1R regulation of hindlimb vascular conductance versus WKY animals. These
in vivo observations were supported by an increased expression of Y1R in skeletal muscle
extracts from SHR while α-AR content was similar to WKY control animals.
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Chapter 3 ‒ Y1 Receptor versus sympathetic control of hindlimb
vascular stiffness in spontaneously hypertensive rats.
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3.1

Introduction
Chapter 2 examined the reaction of the vasculature to the sympathetic agonist’s

phenylephrine (PE) and neuropeptide Y (NPY). The vasculature of young spontaneously
hypertensive rats (SHR) was more responsive to exogenously administered NPY versus
the α-adrenergic receptor agonist PE when compared with normotensive Wistar-Kyoto
rats (WKY). These differences were associated with an increased expression of the NPY
Y1 receptor (Y1R) in SHR animals versus WKYs, while markers of adrenergic signaling
(i.e. α-adrenergic receptor and tyrosine hydroxylase) were unchanged between the strains.
Thus, it was concluded that enhanced Y1R activation may influence the development of
HT in the SHR animal.
Infusing an agonist can expose differences between strains in the responsiveness
of the vasculature to a stimulus through alterations in receptor activation, signal
transduction and/or second messenger signaling. However, this approach provides no
information on the role of that receptor system on baseline or chronic receptor activation.
Alternatively, by antagonizing a receptor, one can prevent signal transduction into the
cell and uncover the role that a specific system (i.e. NPY and the Y1R) plays in both
normal and abnormal conditions. Whereas much emphasis has been placed on
norepinephrine as the major sympathetic neurotransmitter affecting the development of
HT, a growing body of evidence suggests that NPY plays an important role in HT (17;
23; 28; 29). The attention given to NPY is due, in part, to its physiologic actions which
include potent and long-lasting vasoconstriction (27), potentiation of norepinephrine
induced contraction (10), and mitogenesis (1). Each of these actions parallel a
characteristic of established HT (25).
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In 1989, Adams and colleagues (2) reported changes in perfusion pressure across
a range of flow rates that suggested hindlimb vascular remodeling had occurred as early
as 4-6 weeks of age in the SHR; vascular changes that may have even preceded the rise in
blood pressure. This functional evidence of vascular remodeling occurred in concert with
elevated tissue norepinephrine supporting the hypothesis that sympathetic hyperactivity
early in the lifespan of SHR animals is an important contributor to the remodeling
process (2; 16). The mechanism governing this sympathetic hyperactivity in HT is not
clear but probably involves the potentiating impact of sympathetic neurotransmitters on
local vascular growth factors (2; 6). It is notable that vascular remodeling will affect not
only the long-term regulation of blood pressure but also the acute responsiveness of a
vascular bed to neural inputs (22).
Evidence to date has emphasized the role of vascular resistance and the narrowing
of blood vessels as a primary long-term determinant of HT (8; 9; 18). In addition,
vascular stiffness is an important contributor to blood pressure and cardiac work as stiffer
vessels transmit pressure waveforms to and from peripheral reflection points faster than
normal. This causes the reflected pressure waveforms to return to the aorta during
systole, therefore increasing systolic pressure and cardiac work, as opposed to diastole
which actually aides in coronary perfusion (19; 20). Moreover, the role of the heightened
sympathetic outflow on the stiffness and/or resistance of the intact hindlimb vascular bed
in the early stages of HT have not been studied.
Therefore, the purpose of this study was to explore the acute roles of both the Y1R
in particular, and the sympathetic nervous system (SNS) in general, in regulating the
mechanical properties of the rat hindlimb and how each might be modified by HT. We
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tested the specific hypothesis that Y1R activation contributed to vascular stiffness in the
developmental stages of HT in the SHR model. Furthermore, we also tested the more
general hypothesis that sympathetic activation per se (regardless of the neurotransmitters
involved) affected vascular stiffness and viscoelasticity in the SHR hindlimb.

3.2

Methods

Experimental Animals
The following protocol was approved by the Animal Use-Subcommittee at The
University of Western Ontario. Seven week old male Wistar-Kyoto (WKY; 207±16g, n =
7) and spontaneously hypertensive (SHR; 214±15g, n=10) rats were used in this
experiment. Rats were housed in a light (12 h cycle) and temperature (22°C) controlled
room in Plexiglas cages. Rats were allowed to eat (Prolab Rat chow, Mouse and Hamster
3000 Diet) and drink water ad libitum.
Data collection
All animals underwent an acute in vivo vasomotor control study. Animals were
anesthetized with an intraperitoneal injection of α-chloralose (80 mg/kg) and urethane
(500 mg/kg). The mixture of urethane and α-chloralose was used to minimize the impact
of anesthetic on reflex cardiovascular control (14; 15). At a surgical depth of anesthesia,
the right jugular vein was cannulated (PE50 tubing) so as to administer a dilute mixture
of α-chloralose (8-16 mg/kg/hr) and urethane (50-100 mg/kg/hr). Mean arterial pressure
(MAP; mmHg) was measured in the right common carotid artery using a fluid filled
cannula (PE50 tubing) connected to a pressure transducer (model MLT844;
ADInstruments Colorado Springs, CO) and bridge amplifier (model ML118 PowerLab
Quad Bridge Amplifier; ADInstruments). Heart rate (HR; beats/min) was calculated
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online using R-R peaks from sub-dermal ECG electrodes (model FD-E2; Grass
Technologies West Warwick, RI) and a vital signs monitor (model 78353B; Hewlett
Packard Palo Alto, CA) was used in conjunction with blood pressure and temperature
(rectally) to ensure that the animal remained at a stable surgical depth of anaesthesia
throughout the experiment.
The visceral organs were exposed via a midline incision in the abdomen. The
right iliac artery was cannulated (PE50 tubing) to measure blood pressure at the level of
the bifurcation of the aorta. Aortic blood flow (QAorta) was measured just superior to the
bifurcation of the aorta using a flowmeter (model TS420 Perivascular Flowmeter Module;
Transonic Systems, Ithaca, NY) and Transonic flow probe (2.5 PSB). Pulse wave velocity
(PWV; cm/s) was measured as described by Cosson et al. (4). Briefly, the time difference
(T; seconds) between the diastolic foot of the pressure waveform at the carotid (proximal)
and iliac (distal) arteries were measured. The distance (D; cm) between the catheter tips
was measured post mortem, and PWV was calculated as (D/T; cm/s).
Baseline values were measured during a 10 minute period. To test the influence of
the Y1R in baseline cardiovascular control and vascular stiffness, a bolus of the selective
Y1R antagonist N-[(1R)]-4-[(Aminoiminomethyl) amino-1-[[[(4-hydroxyphenyl) methyl]
amino] carbonyl] butyl-a-phenylbenzeneacetamide trifluoroacetate (BIBP3226; 100
µg/kg) was infused into the hindlimb. The peak response to BIBP3226 was measured
approximately 10 minutes following the infusion. Once baseline values were reestablished the neuronal nicotinic acetylcholine receptor agonist hexamethonium bromide
(Hex; 25 mg/kg, Sigma-Aldrich, St. Louis, MO) was introduced systemically to abolish
post-ganglionic nerve activity. Once a new hemodynamic baseline was achieved, 10
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minutes of data were recorded. All drugs were purchased from Sigma-Aldrich (St. Louis,
MO) with the exception of BIBP3226 (Tocris Bioscience; Ellisville, MO).
Data Analysis
MAP (mmHg), HR (beats/min), QAorta (mL/min), PWV (cm/s), and compliance of
the distal aorta (CLocal = [ΔQxΔT]/ΔP; mL/mmHg, Figure 3.1) were calculated. CLocal is a
surrogate of the local compliance at the level of the distal aorta. The traditional method
for assessing cardiovascular regulation is by examining changes in vascular resistance (R)
which, fundamentally, reflects a steady-state level of vascular diameter. Thus, by itself, R
relates information regarding the steady component of blood flow alone (13; 21). Since
blood flow is pulsatile, it incorporates both steady state and oscillatory blood flow (19).
In contrast with R, the stiffness of a vessel, or vascular bed, is related to the oscillatory
nature of blood flow in distensible vessels. In a pulsatile system, it is necessary to
examine the impedance which reflects the frequency-specific resistance and is expressed
in the compliance (C) and viscoelasticity (K) of the vessel wall, and the inertia (L) of
blood and vessel tissue (30). Thus, the vascular resistance (R) and mechanical properties
(C, K and L) of the hindlimb vascular bed were estimated using the aortic flow and
pressure waveforms measured at the distal end of the aorta using a modified Windkessel
model (30; 31). Briefly, the model modifies the values of C, K and L to predict a flow
waveform that would be produced from the measured pressure waveform. The predicted
waveform is then compared iteratively with the measured flow waveform until the best
agreement is achieved, providing the values of C, K and L.
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Figure 3.1 – Calculation of local aortic compliance (CLocal). Beat-by-beat averages of 10
consecutive distal aortic pressure (P, top) and flow (Q, bottom) waveforms were
averaged. CLocal was calculated as the change in flow (ΔQ; mL/min) multiplied by the
time to peak flow (ΔT; min) divided by the pulse pressure (ΔP; mmHg). Thus, CLocal =
[ΔQxΔT]/ΔP; mL/mmHg.
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Statistics
The effects of rat strain (SHR/WKY) and drug (baseline/BIBP3226/Hex) were
compared using a mixed two way analysis of variance (ANOVA; SAS 9.1, Cary, NC,
USA). Statistical significance was accepted at P<0.05. Tukey’s post hoc analysis was
used to identify differences in main effects and interactions. All data are expressed as
mean ± standard deviation.

3.3

Results

Hemodynamics
SHR animals had higher MAP compared to WKYs (Figure 3.2 I; main effect of
strain, P<0.05). BIBP3226 had no effect on MAP in either strain; however following
Hex, MAP fell (main effect of drug, P<0.05 versus baseline and BIBP3226). QAorta was
higher in the WKY animals (data not shown; main effect of strain, P<0.05) and neither
BIBP3226 nor Hex had any effect on QAorta. Vascular resistance (R = MAP/QAorta) was
greater in SHRs compared to the WKYs at baseline and during BIBP3226, but not during
Hex infusion (Figure 3.2 II; strain x drug interaction, P<0.05). BIBP3226 infusion had no
effect on R in either strain, but following Hex R fell in the SHRs only (P<0.05 versus
baseline and BIBP3226 in SHR only).
Systemic Vascular Stiffness
At baseline, PWV was greater in the SHRs compared to the WKYs (Figure 3.2
III; main effect of strain, P<0.05). Compared with baseline, PWV was unaltered
following BIBP3226 infusion but was decreased following Hex in both strains (main
effect of drug, P<0.05 versus baseline and BIBP3226).
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Figure 3.2 ‒ Mean arterial pressure (MAP; I), caudal aortic vascular resistance (R; II)
and pulse wave velocity (PWV; III) from young hypertensive (SHR) and normotensive
(WKY) rats. Values are mean ± standard deviation. *, significantly different from
baseline (within a strain); €, significantly different from BIBP3226 (within a strain); †,
significantly different from WKY baseline; ‡, significantly different from WKY
BIBP3226. Main effect statistics ‒ a, significantly from baseline; b, significantly different
from BIBP3226; c, significantly different from WKY. All statistics P<0.05
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Hindlimb Vascular Mechanics
When compared with WKY, C and CLocal were lower in SHR (Figure 3.3 I and II
respectively; main effect of strain, P<0.05). BIBP3226 infusion had no effect on
hindlimb vascular compliance in either strain (N.S. versus baseline) but both C and CLocal
were increased in both strains following Hex (main effect of drug, P<0.05 versus both
baseline and BIBP3226). K was greater in SHRs compared with WKYs (Figure 3.3 III;
main effect of strain, P<0.05) and K was reduced in both strains following Hex only
(main effect of drug, P<0.05 versus baseline and BIBP3226).
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Figure 3.3 ‒ Hindlimb vascular bed compliance (C; I), local aortic compliance (CLocal; II)
and viscoelasticity (K, III) of the lumped hindlimb vascular beds of young hypertensive
(SHR) and normotensive (WKY) rats. Values are mean ± standard deviation. Main effect
statistics ‒ a, significantly from baseline; b, significantly different from BIBP3226; c,
significantly different from WKY. All statistics P<0.05
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3.4

Discussion
The purpose of this study was to assess the role of the NPY Y1R specifically, and

the SNS generally, in regulating the mechanical properties of the rat hindlimb, and
whether this regulation is modified in the early stages of HT. In particular, emphasis was
placed on the impact of Y1R under baseline conditions. As expected, vascular stiffness
and resistance were greater in the SHR versus WKY animals. These differences were
present regardless of whether the measurements were made locally (e.g., C or CLocal in the
hindlimb) or systemically (e.g., PWV). Contrary to our specific hypothesis the NPY Y1R
has little regulatory control of hindlimb vascular mechanics during developing HT.
Therefore, the SNS does exert some control over the hemodynamic and mechanical
properties of the rat hindlimb, which are presumably mediated by adrenergic and/or
purinergic mechanisms.
Vascular Resistance
Changes in R have been used to reflect vasomotor contractile state and
sympathetic neurovascular control in cardiovascular research for many years (12).
Enhanced SNS activity is routinely seen in HT, and it is suspected that increased R
accounts for some of the augmented pressure (3; 5). This study confirms that the SNS is
responsible for the increased R seen in HT at 7 weeks of age. R was unaffected by Hex in
the normotensive WKY animals which is surprising considering other groups have
reported Hex induced falls in regional vascular resistances in a variety of vascular beds in
WKYs (26). These regional reductions in R were measured in conscious unrestrained
animals therefore; the effect of anaesthesia in reflex cardiovascular control must be
addressed. Data from our lab indicates that the urethane/α-chloralose cocktail used here
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does not impair autonomic reflexes in response to lower body negative pressure
(Usselman et al., In Press). Thus, R in the WKYs appears to be independent of
sympathetic activity at 7 weeks of age.
Vascular Stiffness
A hallmark of HT is vascular stiffening which leads to faster pressure wave
reflections and increased afterload on the left ventricle (20). Here, we have shown that
such stiffening occurs early in the development of HT, namely, in 7-week old SHR
animals, and this stiffening is not restricted to a particular region or level of the vascular
tree but appears to be a generalized feature of SHR at 7 weeks of age. Moreover, changes
in C, CLocal, PWV and K were observed in WKY animals following Hex, without a
change in R. Therefore, the mechanics of the vasculature can be studied independently
from vascular resistance, supporting earlier observations from our lab (30).
Y1R antagonism resulted in little change in PWV, CLocal or hindlimb C in either
strain. Therefore, the current results do not support the hypothesis that Y1R activation is,
by itself, an important contributor to vascular stiffening in SHR. However, ganglionic
blockade did affect hindlimb vascular properties. Nonetheless, an important unresolved
question in the study of the developing of HT is whether the observed stiffening of the
vasculature is due to chronic remodeling or to more acute changes in sympathetic
activation. One interpretation of the current results is that baseline levels of SNS
activation contribute to vascular stiffness in both SHRs and WKYs. However, it is noted
that, following Hex, C and CLocal increased whereas PWV and K fell with a concomitant
fall in MAP. Therefore, the involvement of myogenic contributions to these variables
cannot be ruled out. Additionally, changes in C may reflect the compliance of the
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vascular bed at a different point on the same pressure-volume curve. As such, the changes
in compliance observed may not indicate an actual shift in the mechanical properties of
the vasculature.
Viscoelasticity
To our knowledge, this is the first attempt to examine the impact of sympathetic
control on the viscoelastic properties of the vasculature and how it is affected by HT. The
first observation was that K was much greater in SHR animals compared with WKY
controls at baseline. Thus, viscoelastic resistance to vascular distension is greater in SHR
and could contribute to augmented blood pressure. Second, K was unaffected by Y1R
antagonism but was lower following ganglionic blockade in both strains. Thus, the
augmented K in young SHR appears to be due primarily to neural regulation and not
chronic changes in the vascular wall matrix as would be predicted by vascular
remodeling. In other words, it is the contractile component of the vascular bed that is
causing the elevated value of K in SHR. Thus, the neurogenic regulation of K may be
treated as an abnormality associated with the HT. This supposition awaits further
experimentation as altered vascular wall structure may also affect its contractile
properties (22).
Limitations
A major limitation to this study is the absence of measured sympathetic nerve
activity. Thus, it is assumed that sympathetic outflow was elevated in the SHR animals,
an assumption that has been validated previously (see (7) for a detailed review).
Using a chemical agent to antagonize ganglionic neural transmission, we can
reasonably assume that complete ganglionic blockade occurred with Hex as previously
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published reports (11; 24) indicate that 20mg/kg was a sufficient dose to completely
block post-ganglionic neural transmission as measured in the renal nerve in both SHR
and WKY animals.

3.5

Conclusion
The current results suggest that the increased vascular resistance in 7-week old

SHR animals is neurally mediated, but does not involve the NPY Y1R. Markers of
vascular stiffness (C, CLocal, K, and PWV) displayed some neural control in both strains,
but again, the Y1R did not participate. Thus, it appears that neural activation contributes
to baseline vascular stiffening and resistance in early stages of hypertension. However,
this neural involvement does not include Y1R activation. Nonetheless, levels of hindlimb
R in 7-week old WKY animals appear to be independent of neural activation. These
observations contrast with the prolonged Y1R activation in young SHR in response to
agonist infusion and highlight the importance of non-NPY sympathetic neurotransmitters
in chronic vasomotor control in young SHR. Therefore, the current results suggest that
increased vascular stiffness is evident early in HT, and this stiffening appears to be under
neural control.
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Chapter 4 ‒ Sympathetic Contribution to Peripheral Vascular Stiffness
in Young Female Spontaneously Hypertensive Rats.
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4.1

Introduction
The etiology of essential hypertension (HT) is complex and includes both a

sustained increase in sympathetic nervous system (SNS) activity (4; 10; 22; 34; 44) that
begins early in life (3; 8; 38), and a remodeled vascular bed (25). Evidence is growing
which indicates that male and female animals differ in a number of physiological
parameters (12; 13; 24; 26; 35), but the reason for these differences remains unknown.
This chapter explores the mechanical properties of the vasculature during development of
HT in young female animals. As figure 1.6 indicates, the prevalence of HT in humans
displays sexual dimorphism. These differences are evident in the youngest age bracket
(20-34 years) which indicates that the processes responsible are present throughout life,
but appear to change with age (1). Unlike chapters 2 and 3, this chapter does not include
agonist or antagonist interventions, but focuses solely on hemodynamic and mechanical
properties of the vasculature at baseline and following the administration of
hexamethonium bromide. Agonist stimulation was not included in the analysis because
stable hindlimb blood flow values were unattainable in young female animals (See
Appendix A.1). Also, antagonism of the neuropeptide Y (NPY) Y1 receptor (Y1R) was
not performed, because, the NPY and Y1R system contributes little to baseline blood flow
control in female rats (13-15), and also because chapter 3 suggests that the Y1R does not
regulate the mechanical properties of the vasculature.
It is generally accepted that enhanced SNS activity and vascular remodeling,
combine to enhance blood pressure through changes in vascular resistance (R) and
stiffness (2; 6; 27; 32) (Figure 4.1). However, R reflects vascular resistance to only the
steady component of blood flow (17; 31) and, therefore, has limited diagnostic function
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in the context of the oscillatory component of blood flow (29). To better understand the
mechanisms responsible for controlling pulsatile (steady plus oscillatory) blood flow, it is
necessary to consider the impedance rather than R (40). The impedance in pulsatile blood
flow involves R, but also the compliance (C) and viscoelasticity (K) of the vessel wall,
and the inertia (L) of blood and vessel tissue (41). These properties are involved in the
regulation of blood flow, yet the role that the SNS plays in regulating C and K has yet to
be elucidated (Figure 4.1). Previously, it was shown that the brachial artery (33) and the
forearm vascular beds (41) of humans stiffen during reflex maneuvers that elevate
sympathetic outflow. The particular impact of sympathetic neural control of vascular
mechanics was not assessed in these earlier studies. Thus, the neurogenic regulation of
vascular mechanics is not known in either central or peripheral vascular beds, particularly
in the context of developing HT. Also, little is known about the role of vascular
remodeling in modifying neurogenic vasomotor control. Vascular remodeling is typically
manifest as vascular smooth muscle hypertrophy (11), leading to wall thickening and
increased arterial stiffness. In common practice, vascular stiffness is determined by
measuring pulse wave velocity (PWV) along an arterial segment (9; 21) and is then used
as a global measure of vasular stiffness. In this process, the measure of PWV does little
to determine whether the stiffness is located centrally or peripherally, or what the root
cause of the stiffness is in terms of mechanical properties of the vessel wall that affect its
stiffness.
Hypertension develops early in the life of spontaneously hypertensive rats (SHR;
approximately 5-weeks of age) where an elevated sympathetic outflow is often observed
(23). Also, neonatal sympathectomy is known to consistently prevent the development of
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high blood pressure in SHR (18; 37). Thus, while the involvement of the sympathetic
nervous system in HT is generally suspected, little is known about how the SNS actually
participates in the development of the disease. Furthermore, in general, more is known
about HT in male rats, but little is known about the disease in young female rats.
The aim of our study was to explore the role of the SNS in both central arteries
and peripheral vascular beds of young normotensive and hypertensive female rats. In
conjunction with measures of PWV, we quantify C, K, and L in the hindlimb vascular bed
of the spontaneously hypertensive rat (SHR) and thus examine the role of the SNS in
regulating their values. With this approach we tested the hypotheses that a) vascular
stiffness and viscoelasticity are under neurogenic regulation, and b) that this regulation is
modified during the development of HT.

Figure 4.1‒ Schematic of currently accepted (solid arrows) and proposed (dashed arrows) pathways for the effects of sympathetic
nerve activity on mean arterial pressure.
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4.2

Methods

Animals
This protocol was approved by the Animal Use Subcommittee at the University of
Western Ontario. Young female Wistar-Kyoto (WKY; 148±7g, n=7) and Spontaneously
Hypertensive (SHR; 134±6 g, n=6) rats were used in this experiment (Charles River
Laboratories, Montreal, Canada). Rats were housed in a light (12 h cycle) and temperature
(22°C) controlled room in Plexiglas cages. Rats were allowed to eat (Prolab Rat chow,
Mouse and Hamster 3000 Diet) and drink water ad libitum.
Data Acquisition
At approximately 7 weeks of age animals were anesthetized by an intraperitoneal
cocktail of α-chloralose (80 mg/kg) and urethane (500 mg/kg) to ensure minimal impact
on reflex cardiovascular control (19; 20). Once a surgical depth of anaesthesia was
achieved, the right jugular vein and common carotid artery were exposed and cannulated
with PE50 tubing to allow the delivery of dilute anaesthetic (α-chloralose 8-16 mg/kg/hr
and urethane 50-100 mg/kg/hr) and measure arterial blood pressure (pressure transducer
model MLT844, quad bridge amplifier model ML118; ADInstruments Colorado Springs,
CO), respectively. Heart rate (HR; beats/min) was calculated online using R-R peaks
from sub-dermal ECG electrodes (model FD-E2; Grass Technologies West Warwick, RI)
and a vital signs monitor (model 78353B; Hewlett Packard Palo Alto, CA) was used in
conjunction with blood pressure and temperature (rectally) to ensure that the animal
remained at a stable surgical depth of anaesthesia throughout the experiment.
A midline incision was made in the abdomen to expose the visceral organs. The
right iliac artery was cannulated with PE50 tubing. The cannula was inserted rostrally to
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measure blood pressure at the bifurcation of the aorta into the two iliac arteries. Aortic
blood flow (QAorta) was measured just superior to the bifurcation of the aorta using a
flowmeter (model TS420 Perivascular Flowmeter Module; Transonic Systems, Ithaca,
NY) and Transonic flow probe (2.5 PSB). PWV was measured as described by Cosson et
al. (5). Briefly, the time difference (T; seconds) between the diastolic foot of the pressure
waveform at the carotid (proximal) and iliac (distal) arteries were measured. The distance
(D; cm) between the catheter tips was measured post mortem, and PWV was calculated
as (D/T; cm/s).
The animals were allowed to recover from surgery for 1 hour. Baseline values
were measured during a 10 minute period after which the neuronal nicotinic acetylcholine
receptor agonist hexamethonium bromide (Hex; 25 mg/kg, Sigma-Aldrich, St. Louis,
MO) was introduced systemically to abolish post-ganglionic neural activity. Once a new
hemodynamic baseline was achieved, 10 minutes of data were recorded.
Following data acquisition, animals were euthanized with an overdose of
anaesthetic. Femoral arteries were harvested distal to the inguinal crease, cleaned of
excess connective tissue, stabilized overnight in 15% sucrose, and then fixed overnight in
10% neutral buffered formalin (HT501320, Sigma-Aldrich). Fixed arteries were mounted
in clear frozen section compound (VWR, Cat. No. 95057-838) and snap frozen. Mounted
arteries were sectioned (7µm) using a Lauda-Leitz (model 1720) digital kryostat,
mounted on Fisherbrand Superfrost/plus microscope slides (Cat. No. 12-550-15), and
stained using a Modified Verhoeff Van Gieson Elastic Stain Kit (HT25A, SigmaAldrich).
Data Analysis
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Mean arterial pressure (MAP; mmHg), HR (beats/min), QAorta (mL/min), pulse
wave velocity (PWV; cm/sec), and local compliance of the aorta (CLocal = [ΔQxΔT]/ΔP of
the distal aorta; mL/mmHg, See Figure 3.1) were calculated. CLocal was used as a local
measure of compliance at the level of the distal aorta. The vascular resistance (R) and
mechanical properties (C, K and L) of the hindlimb vascular bed were assessed using the
measured aortic flow and pressure waveforms in conjunction with a modified Windkessel
model (41; 42). Briefly, the model predicts the flow waveform that would be produced by
the measured pressure waveform. The predicted waveform is then compared with the
measured flow waveform to determine the values of C, K and L (see Figure 1.5).
Sections of femoral artery were visualized using a Zeiss Axiovert S100
microscope, with a Sony Power HAD 3CCD colour video camera. Femoral artery wall
thicknesses were measured using Northern Eclipse V8 (Empix Imaging Inc.,
Cheektowaga, NY, USA).
Statistics
The effects of rat strain (SHR/WKY) and drug (baseline/Hex) were compared
using a mixed two way analysis of variance (ANOVA; SAS 9.1, Cary, NC, USA). Main
effects of the ANOVA (SHR/WKY and baseline/Hex) were considered significant at
P<0.05, and where interactions in the ANOVA were significant, again at P<0.05,
Tukey’s post hoc analysis was used to identify differences. Wall thicknesses were
compared using an unpaired, equal variance Student’s T-Test. Data are presented as mean
± standard deviation.

4.3

Results

Hemodynamic alterations following Hex
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The results confirm that the hypertensive animals used in the experiment had
higher baseline MAP compared to WKY animals (Figure 4.2 I; P<0.05 at baseline).
Following Hex, MAP fell in both strains (P<0.05) but to a larger extent in SHRs,
resulting in similar MAP between strains (not significant; N.S. following Hex). QAorta was
higher in the WKYs, (Figure 4.2 II; P<0.05); however, some of this difference can be
attributed to the larger size of the WKYs compared to the SHRs (148±7g versus 134±6g,
respectively; P<0.05). Systemic vascular resistance (R = MAP/QAorta) was greater in
SHRs compared to the WKYs (Figure 4.2 III; main effect of strain; P<0.05), and Hex
lowered R in both strains (main effect of drug; P<0.05). PWV was higher in SHR
animals at both baseline and following Hex (Figure 4.2 IV; both P<0.05), but Hex caused
a reduction in PWV in both strains (P<0.05).
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Figure 4.2 ‒ Mean arterial pressure (MAP; I), caudal aortic flow (QAorta; II), caudal aortic
vascular resistance (R; III) and pulse wave velocity (PWV; IV) from young female
hypertensive (SHR) and normotensive (WKY) rats. Hex, hexamethonium. Values are
mean ± standard deviation. *, Significantly different from baseline, P<0.05; †,
Significantly different from WKY baseline, P<0.05; ‡, Significantly different from WKY
Hex, P<0.05. Main effect statistics: a, denotes P<0.05 versus baseline; b, denotes
P<0.05 versus WKY.
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Mechanical alterations following Hex
When compared with WKY, the SHR animals had lower C and CLocal (Figure 4.3
I and 4.3 II respectively; main effect of strain P<0.05) and higher K values (Figure 4.3
III; main effect of strain P<0.05). Compared with baseline, both C and CLocal increased
only in the WKYs following Hex (Figure 4.3 I and 4.3 II respectively; P<0.05).
However, Hex had little effect on C or CLocal in SHRs and failed to modify K in either
strain (Figure 4.3 III; N.S.). Wall thickness for WKY (n=4) animals was 33.5±6.3µm
versus 48.9±7.4µm in the SHR (n=4) (Figure 4.4; P<0.05; β=0.930).
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Figure 4.3 – Hindlimb vascular bed compliance (C; I), local aortic compliance (CLocal; II)
and viscoelasticity (K, III) of the lumped hindlimb vascular beds of young female
hypertensive (SHR) and normotensive (WKY) rats. Hex, hexamethonium. Values are
mean ± standard deviation.*, Significantly different from baseline, P<0.05; †,
Significantly different from WKY baseline, P<0.05 ‡, Significantly different from WKY
Hex P<0.05. Main effect statistics: b, denotes P<0.05 versus WKY
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Figure 4.4 ‒ Ex vivo, unpressurized femoral artery wall thickness from young female
hypertensive (SHR) and normotensive (WKY) rats. Top: group averages of SHR and
WKY animals. Bottom: representative SHR (left) and WKY (right) ex vivo unpressurized
femoral arteries at 20X magnification. †, Significantly different from WKY, P<0.05.
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4.4

Discussion
The purpose of this study was to examine the role of the SNS in the central

arteries and peripheral vascular beds of young normotensive and hypertensive female
rats. It was observed that the lumped compliance of the hindlimb vasculature of young
female WKY animals increased following ganglionic blockade, indicating that peripheral
vascular stiffness was affected by SNS input. By contrast, it was observed that SHRs had
lower C and higher K, meaning stiffer peripheral vascular beds with higher resistance to
stretch, both before and following ganglionic blockade. Thus, it appears that the normal
neurogenic control of vascular stiffness is lost in the developmental period of SHR (i.e.,
within 7 weeks of age). This loss of neurogenic control was associated with vascular
remodeling in the SHR, again, at the early age of 7 weeks. These data support the overall
hypothesis that vascular stiffness is under some level of neurogenic control but that this
control is modified in the developmental stages of HT in females.
Previously, it was demonstrated that brachial artery compliance of humans (33)
and the lumped compliance of the entire human forearm vascular bed (41) are under
some neural control, where sympathoexcitatory reflex maneuvers consistently reduced C.
The current results from a rodent model provide new experimental evidence that the
compliance (C and CLocal) of peripheral vascular beds are (normally) under some neural
control as well, supporting these earlier results from humans. However, the current
results show further that this neural control of vascular stiffness and viscoelasticity
appears to be “lost” in HT. This observation supports the scenario proposed in Figure 4.1
whereby reduced compliance and increased viscoelasticity, possibly due to the trophic
actions of neurotransmitters (7; 43), add to hypertension by means of faster wave
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reflections reaching the aorta during systole which increases the afterload of the left
ventricle (30).
It is particularly important that the value of K in SHR was found to be higher than
that observed in the WKY group because this property represents viscoelastic resistance
to stretch within the vessel wall which is over and above that of pure elasticity. While the
concept of viscoelasticity is not new (28), the components of the vessel wall that account
for changes in this important mechanical property, or differences among populations,
remain largely unknown. Yin and colleagues (39) observed differences in the viscoelastic
properties such as the stiffness modulus and phase lag (force-length relationships) in
young and senescent arterial strips from dogs. They noted that although the stiffness was
increased in the senescent animals, the differences observed could not be accounted for
by changes in the content of elastin, collagen, or the ratio of the two. Our results suggest
that vascular remodeling (at least in Ex vivo, unpressurized femoral arteries) may play a
role in augmenting K.
Finally, the dichotomy between the roles of central arteries versus peripheral
vasculature in the control of blood pressure deserves emphasis. It is well accepted that the
resistance of the central vessels makes up a negligibly small part of total resistance
because of their relatively large diameters. On that basis, it is reasonable to suspect that
central vascular radii are not under acute SNS control, although it is known that the SNS
exerts chronic (trophic) effects on all vascular beds, which can lead to vascular
remodeling (7). The question then arises as to whether the compliance and viscoelasticity
of the central arteries are also under these trophic effects or under SNS control. The wall
thickening observed in the femoral artery, the higher PWV following Hex, and the
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increased stiffness in the distal aorta, as measured by CLocal, all point to a remodeled
vascular system that is not necessarily confined to the peripheral vasculature. Thus, by 7
weeks of age, there is progressive remodeling present in the SHR model. It is likely that
the mechanisms of such remodeling include pressure-induced hypertrophy and the
trophic effects of chronic SNS activity. The way in which these factors combine to
induce the stiffening and remodeling observed in HT remains unknown. However, our
study supports the potential role of the SNS in the pathogenesis of HT.
Limitations
The interpretation of the results obtained here is based on the assumption of
complete neural blockade by Hex. The fall in R and MAP following ganglionic blockade
with Hex provide evidence of ganglionic antagonism. Also, the dose of Hex used here
was higher than that of previously published reports (16; 36) in which 20mg/kg of
intravenous Hex abolished (renal) sympathetic nerve activity in both SHR and WKY
animals between 15 and 20 weeks of age.
Additionally, because of the observed falls in MAP following Hex, changes in C
might reflect a shift along the same pressure-volume curve, and may not be indicative of
an actual change in the mechanical properties of the vasculature (i.e. shift of the pressurevolume curve).

4.5

Conclusions
The current results indicate that vascular compliance of the peripheral vascular

bed is regulated in part by the nervous system but that this control is lost in SHR in
conjunction with vascular remodeling. The way in which the remodeled vascular bed and
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aorta affect this neurogenic regulation is not known, but it was noted that this altered
neurovascular control was evident already by 7 weeks of age in the SHR group.
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Chapter 5 ‒ Evidence for sexual dimorphism in sympathetic control of
vascular function.

113

5.1

Introduction
The preceding chapters have outlined studies which examined the role of the

sympathetic nervous system (SNS) in the early stages of hypertension (HT). The designs
of the studies were limited to either male or female animals as there was no initial
intention to include male/female comparisons. However, during data collection and
analysis of the studies, striking differences were observed in the hemodynamic and
hindlimb mechanical properties of the male and female rats. In particular, female animals
exhibited higher baseline heart rate (HR) and mean arterial pressure (MAP), but the most
striking differences were lower levels of hindlimb compliance (C), and local aortic
compliance (CLocal), with much higher viscoelasticity (K). In essence, female animals
appeared to have much stiffer peripheral vascular beds compared to their age matched
counterparts.
Sex differences have been reported in a number of (patho-) physiologic conditions
including incidence of cardiovascular disease, systemic inflammation, systemic lupus
erythematosus and type-2 diabetes (3; 4; 7; 21). Recently, Hart et al. (11) demonstrated
that the relationships between muscle sympathetic nerve activity, cardiac output and
vascular resistance, relationships that are often seen in males, break down in females.
Similarly, females exhibit less vascular responsiveness to intra-arterial infusions of
norepinephrine compared to males (18), and observations from rodent studies suggest
that, in contrast to males, females lack baseline neuropeptide Y (NPY)-mediated control
of hindlimb vascular conductance (12-14). Additionally, chapters 3 and 4 indicate that the
mechanical properties of the rat hindlimb are regulated by the SNS, but the magnitude of
the differences observed in the values C, CLocal and K between males and females are
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striking. These examples of sexually dimorphic regulation by the SNS suggest that male
and female animals may utilize different mechanisms of vascular control. Therefore the
purpose of this study was to explore the differences observed in the systemic
hemodynamics and hindlimb vascular mechanics of male and female rats, and how neural
cardiovascular regulation might differ between the sexes.

5.2

Methods
A retrospective analysis of data from chapters 3 and 4 was performed in which the

hemodynamic and lumped hindlimb vascular mechanics of male and female rats was
assessed for sex-based differences. Spontaneously hypertensive (SHR; male n=10, female
n=7) and Wistar-Kyoto (WKY; male n=6, female n=7) rats from both sexes underwent
identical anaesthesia and surgical procedures as previously outlined (chapters 3 and 4).
Briefly, the animals were anesthetized with an intraperitoneal injection of urethane
(500mg/kg) and α-chloralose (80mg/kg). Animals were instrumented to measure blood
pressure at the carotid artery, and at the bifurcation of the aorta into the iliac arteries.
Blood flow was measured just superior to the bifurcation of the aorta.
Mean arterial pressure (mmHg), HR (beats/min), aortic blood flow (QAorta,
mL/min), caudal conductance (CondCaud, mL/min/mmHg), pulse wave velocity (PWV,
cm/s) and CLocal (mL/mmHg) were calculated (see chapters 3 and 4). The vascular
resistance (R) and mechanical properties (C, K and L) of the hindlimb vascular bed were
also assessed (see chapters 3 and 4). C and CLocal were normalized to body weight to
account for differences in the volume of vasculature tissue between the sexes. All
variables were measured or calculated at baseline and following the administration of
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hexamethonium bromide (Hex; 25mg/kg) to abolish post-ganglionic neural transmission.
All animals were 7 weeks of age at the time of the surgical interventions.
Statistics
Data were analyzed at baseline and during Hex using a mixed two-way Analysis
of Variance (ANOVA; SAS 9.1, Cary, NC, USA) on sex (male/female) and strain
(SHR/WKY). The response to Hex was compared to baseline using a paired Student’s ttest. Main effects of the ANOVAs and t-test were considered significant at P<0.05, and
Tukey’s post hoc analysis was used to identify where differences occurred in the
ANOVA. Data are presented as mean ± standard deviation.

5.3

Results
Baseline hemodynamics and body weight can be found in Table 5.1. Main effects

of sex and strain were observed for MAP, HR, QAorta, CondCaud, and R (all P<0.05).
MAP, HR and R were higher in SHRs versus WKYs and in females compared to males.
Aortic blood flow and CondCaud were lower in SHRs versus WKYs and were higher in
males. Figure 5.1 depicts PWV (Figure 5.1, I), weight normalized C and CLocal (Figure
5.1 II and III, respectively) and lumped hindlimb K (Figure 5.1, IV). Compared with
WKY PWV was higher in SHRs (main effect of strain, P<0.05) but was not different
between the sexes. Females displayed lower C and CLocal compared to males (main effect
of sex, P<0.05); however, the difference in C was abolished when normalized to body
weight (CLocal remained lower in females). C and CLocal were lower in SHRs (main effect
of strain, P<0.05) and this difference remained following normalization. Females had
higher K values compared to males (interaction effect, P<0.05) and in SHRs were higher
than WKYs (interaction effect P<0.05).
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Response to Hex
The percent change from baseline for MAP, HR, QAorta, CondCaud and R can be
found in Table 5.2. Mean arterial pressure fell in response to Hex in all groups except
male WKYs (t-test, P<0.05). Heart rate rose in all groups except female SHRs following
Hex (t-test, P<0.05). Aortic flow fell in female SHRs only (t-test, P<0.05), while
CondCaud rose and R fell in both male and female SHRs (t-test, P<0.05).
Pulse wave velocity fell in all groups following Hex (t-test, P<0.05; Figure 5.2 I).
The weight corrected hindlimb C and CLocal rose in all groups except Male WKYs (t-test,
P<0.05; Figure 5.2 II and III respectively) and K fell in all groups except female SHRs (ttest, P<0.05; Figure 5.2 IV).
Comparisons in Hex
Following Hex administration the SHRs animals had a larger change in MAP
compared to WKYs (main effect of strain, P<0.05) and female animals had a greater fall
compared to males (main effect of sex, P<0.05).The increase in HR was greater in male
animals compared to females (main effect of sex, P<0.05). A significant interaction of
sex and strain was seen in QAorta, CondCaud and R following Hex, in that male SHRs and
WKYs were significantly different from one another in each variable. Additionally, QAorta
was significantly different between male and female SHRs, and R was significantly
different between male and female WKYs (all P<0.05). PWV fell more in males than in
females (main effect of sex, P<0.05) and there were no differences in the response to
Hex in any group for C, CLocal, or K.
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Table 5.1 ‒ Weight (g), mean arterial pressure (MAP), heart rate (HR), aortic flow
(QAorta), caudal conductance (CondCaud) and caudal resistance (R) in male and female
spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats.
Male

Female

SHR (n=10) WKY (n=7)

SHR (n=6) WKY (n=7)

Weight (g)

207±16 a

214±15

134±6 a,b

148±7 b

MAP (mmHg)

86±13 a

64±5

91±6 a,b

78±7 b

HR (beats/min)

339±29 a

302±81

388±24 a,b

333±25 b

QAorta (mL/min)

5.7±2.0 a

9.5±3.2

2.7±0.6 a,b

5.7±2.3 b

CondCaud (μL/min/mmHg)

68±26 a

147±43

30±6 a,b

75±35 b

R (mmHg/mL/min)

17.6±7.0 a

7.7±3.3

31.5±7.1 a,b

15.4±5.7 b

All of the variables listed have significant main effects of sex and strain (both
P<0.05). Values are mean ± standard deviation. Main effect statistics: a, P<0.05
versus WKY; b, P<0.05 versus male.
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Figure 5.1‒ Pulse wave velocity (PWV; I), weight normalized hindlimb compliance (C;
II), weight normalized local aortic compliance (CLocal; III) and lumped hindlimb
viscoelasticity (K; IV) from male and female spontaneously hypertensive (SHR) and
normotensive Wistar-Kyoto (WKY) rats. Values are mean ± standard deviation. *
denotes P<0.05 versus WKY (within a sex), † denotes P<0.05 versus male WKY; ‡
denotes P<0.05 versus male SHR. Main effect statistics: a, P<0.05 versus WKY; b,
P<0.05 versus male.
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Table 5.2 ‒ Percent change from baseline following ganglionic blockade with
hexamethonium bromide (Hex; 25mg/kg) on mean arterial pressure (MAP), heart rate
(HR), aortic flow (QAorta), caudal conductance (CondCaud) and caudal resistance (R) in
male and female spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats.
Male

Female

SHR

WKY

SHR

WKY

MAP (% Δ)

-11±13†a

4±9

HR (% Δ)

9±7†

26±12†

-4±7b

7±6†b

QAorta (% Δ)

22±36†

-5±28

-14±13†

-6±18

CondCaud (% Δ)

36±37†*

-9±24

19±17†

14±23

R (% Δ)

-24±16†*

14±28

-11±14†

-14±17

-28±7†a,b -17±7†b

Main effect of sex and strain for MAP, main effect of sex for HR and interaction effect
for CondCaud, QAorta and R (all P<0.05). Values are mean ± standard deviation. † denotes
significantly different from baseline (t-test, P<0.05). * denotes P<0.05 versus WKY
(within a sex). Main effect statistics: a, P<0.05 versus WKY; b, P<0.05 versus male.
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Figure 5.2 ‒ Percent change from baseline of pulse wave velocity (PWV; I), weight
normalized hindlimb compliance (C; II), weight normalized local aortic compliance
(CLocal; III) and lumped hindlimb viscoelasticity (K; IV) from male and female
spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats
following ganglionic blockade with hexamethonium bromide (Hex; 25mg/kg). Values are
mean ± standard deviation. † denotes significantly different from baseline (t-test,
P<0.05). Main effect statistics: b, P<0.05 versus male. Note that CLocal had a significant
interaction, however no group differences were identified in the post hoc analysis.
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5.4

Discussion
The main finding of the current study was that female rats have higher resistance

(R) and viscoelasticity (K) in peripheral vascular beds relative to age-matched males.
Some of the dimorphism was driven by the SNS, but other factors also play a role. Sexual
dimorphism was particularly evident in baseline MAP, HR, R, CLocal and K. These sexdependent differences were apparent in both normotension and HT indicating that they
are not strain dependent.
Higher MAP in female animals, compared with male animals, was present in both
SHRs and WKYs and was largely mediated by neural input in females and in HT. Male
WKYs showed no change in MAP following Hex, but showed marked tachycardia.
Conversely, female SHRs had a large fall in MAP with no change in HR following Hex.
These divergent responses suggest different control mechanisms in male and female rats,
which become amplified in female HT. Specifically, male normotensive rats display
parasympathetic (PNS) control of the heart at baseline as ganglionic ablation increased
HR in accordance with PNS withdrawal (10; 19). In contrast, female hypertensive rats
appear to have altered autonomic control of the heart at baseline, in that ganglionic
blockade had no effect on HR. The large fall in MAP with Hex in female SHRs was not
accompanied by a large fall in R as QAorta declined modestly. This latter observation
suggests reduced cardiac contractility with Hex in the female SHR animals, rather than a
PNS withdrawal mechanism.
The observed high R and low CLocal in female rats mirror human data from our lab
(37). In this earlier study, using the same mathematical model, young subjects and HT
patients were analyzed. The females (regardless of group) displayed higher R and lower
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C relative to males. Also, K was markedly higher in the human HT patients (37) which
parallels the results presented here in the SHR model. To date, no one has reported sex
differences in vascular viscoelastic properties. The results presented here show striking
sex differences in the viscoelasticity, which represents the resistance to stretch in the
blood vessels. This property of the vessel wall is not well understood in either health or
disease. It is apparent that viscoelasticity is calcium dependent (28; 29) indicating that the
cross-bridge attachment within vascular smooth muscle cells (VSMC) is a key factor in
its regulation. The current study also emphasizes that the SNS can influence K and that
the control is modified by sex and in disease (i.e. female SHR). Such differences may be
influenced by sex-dependent differences in VSMC structure and signaling cascades (16;
22). Specifically, reduced Ca2+ handling and a blunted expression and activation of
protein kinase C (PKC) in VSMCs from female animals, leads to less contraction relative
to male animals. How these alterations affect K, or its regulation, remains unclear.
Estrogen is a likely candidate mediating the sexual dimorphism seen here. The
role of estrogen in regulating vascular stiffness is complex. Reports of both increased and
reduced levels of vascular stiffness by estrogen supplementation have been reported (25;
26; 32; 35). Further, estrogen manipulation does have the ability to alter resting VSMC
structure, intracellular Ca2+ concentrations and PKC expression to levels that are similar
to males (16; 22; 24). Indeed these results are further confounded, as the type of estrogen
used, the method of delivery and previous estrogen exposure all influence the outcome
(8; 31). Despite these conflicting reports, estrogen does impact vascular stiffness, and
does impact sympathetic vascular control (36; 38; 39).
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To further address the direct effect of estrogen, a secondary study was performed
on small groups of female animals in which estrogen levels were manipulated by
ovariectomy (OVX; n = 6) and ovariectomy + estrogen replacement (OVX+E2; 0.25mg
17β-estradiol [3-week release]; n = 6). The data are provided in Appendix A.2. Briefly, a
main effect of estrogen manipulation was observed in C and a strain x estrogen
interaction was observed for PWV. Neither OVX, nor OVX+E2, had altered hindlimb
mechanics relative to intact controls in either strain of rat. However, point-wise
comparisons between OVX and OVX+E2 suggest that OVX tended to reduce indices of
stiffness (C and PWV), while OVX+E2 tended to increase stiffness, particularly in HT.
A main effect of strain was observed for MAP and again when point wise comparisons
were made, OVX had lower MAP compared to OVX+E2 in SHRs. These results suggest
that estrogen is an important factor in regulating the increased stiffness seen in female
rats, at least in SHRs. However, it is clear that dosages of estrogen replacement must be
titrated carefully in order to properly mimic the intact animal.

5.5

Perspectives
The sexual dimorphism of vascular bed mechanics reported here, combined with

reports of similar sex-specific differences in vascular reactivity to sympathetic stimuli
(12; 13; 18), suggest that female animals may rely on different mechanisms to regulate
vascular function. Males appear to sympathetically control vessel diameter (i.e.
alterations in vascular resistance) to regulate blood pressure, while the stiffer vasculature
seen in female animals suggests a greater reliance on central (or cardiac) mechanisms.
This mechanism has been observed previously, when, in response to lower body negative
pressure (5) and progressive tilt (27), females demonstrate an exaggerated heart rate
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response, and lower sympathetic nerve activation, despite the same level of
hemodynamic stress. Additionally, females have shown greater cardiac responsiveness
versus peripheral vascular reactivity to a variety of stressors (1; 9), and exhibit
exaggerated vascular contraction to non-adrenergic/sympathetic antagonists (6; 30; 33)
compared to males.
Female rats appear to lack the NPY mediated control of baseline hindlimb
conductance which is present in males (12; 13). Estrogen appears to be involved in
regulating the (lack of) NPY response in females. Recent work by Jackson et al. (15)
examined the sympathetic hindlimb conductance response in female Sprague Dawley rats
that were either intact, were ovariectomized, or were ovariectomized but had
supplemental estrogen. They reported that following ovariectomy, the expression of both
NPY and the NPY Y1 receptor (Y1R) were increased, as was the Y1R control of hindlimb
vascular conductance. These adaptations were prevented by the supplementation of
estradiol (15) suggesting that estradiol plays a critical role in regulating sympathetic
cardiovascular control.
In the vasculature NPY produces a potent and long lasting vasoconstriction and
potentiates the effects of norepinephrine (20; 34). In male animals, based on the increased
hindlimb conductance response to Y1R antagonism, we can presume that these
contractions are present at baseline (14) and may act to stabilize the vasculature over
many cardiac cycles. The stiffer vasculature observed in females would work in much the
same fashion, buffering beat-to-beat fluctuations, with little need for neural input. Thus,
the need for NPY mediated baseline control of the hindlimb is absent and the system is
down regulated (12; 13), and may account for the lower level of baseline sympathetic
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nerve activity that is commonly observed in females (Figure 5.3), as stiffer arteries would
require less neural input.
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Figure 5.3 ‒ Matched female (A) and male (B) baseline neurograms of muscle
sympathetic nerve activity (MSNA) measured in the peroneal nerve. Data generously
provided by Ruma Goswami.

127
Limitations
The dichotomous mechanisms of cardiovascular regulation proposed here are
based on a limited number of observations in a young rodent population. Thus, the
phenomenon mentioned may be the result of differences of the natural development of
male and female animals, and may not reflect a distinct sex difference. Indeed, increased
levels of endogenous estrogen and testosterone in males and females, respectively, have
been associated with altered vascular stiffness in pre- versus post-pubertal humans (2).
As the animals here were post-pubescent (17; 23) it is unlikely that the endogenous levels
of estrogen and/or testosterone factored into the differences seen, although measurement
of endogenous estrogen and testosterone is required for confirmation. Additionally, as the
animals were measured at the same age (instead of weight), were housed in the same
location and exposed to the same diet, it is unlikely that environmental or developmental
factors can account for the increased stiffness observed in female animals. Much more
work is required in order to ascertain whether the increased stiffness in female animals is
a physiologically relevant mechanism of cardiovascular control.

5.6

Conclusions
This retrospective analysis of data presented in chapters 3 and 4 suggests that

dichotomous mechanisms of cardiovascular control exist between male and female
animals. Female animals exhibited augmented MAP and HR relative to males in
conjunction with greater stiffness and viscoelasticity in both SHR and WKY animals.
The impact of K on blood pressure control is unknown, but this parameter may be a
critical feature in female hypertensive animals.

128
Differential control of the heart in male and female animals is suggested
following ganglionic blockade and an increase in compliance and reduced K following
Hex suggest that both of these variables are affected by agonist-induced intracellular
calcium levels. The more compliant vascular beds of male animals may require greater
neural input to maintain vascular homeostasis compared to the stiffer female animals.
Females apparently rely on central (cardiac) mechanisms to regulate blood pressure,
while males would rely on sympathetically mediated changes in vessel caliber to alter
vascular resistance. It may be that these differences are due to altered vascular mechanics
(or vice versa).
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Chapter 6 ‒ General Discussion and Conclusions
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6.1

Overall Summary
The primary aim of this body of research was to explore the role of the

sympathetic nervous system (SNS) in regulating the cardiovascular system during the
development of hypertension (HT). Through the actions of both norepinephrine (NE) and
neuropeptide Y (NPY), the SNS elicits both acute and chronic effects on the vasculature.
Much is known about how these neurotransmitters interact with the vasculature during
both normotension and developed HT, but the way in which these critical
neurotransmitters control the vasculature as HT develops remains unclear.
The SNS’s involvement in HT fundamentally occurs through heightened
sympathetic activity leading to increased vascular resistance (3; 18). NE and the αadrenergic receptor (α-AR) are the classic mediators of the augmented resistance (10;
32). Data presented in chapter 2 highlight an exaggerated role for the NPY-mediated
signaling in the early stages of the HT (at least in male animals). This enhanced NPYmediated control was absent at 3-5 weeks of age, but present at 7 weeks, suggesting that
alterations in sympathetic signaling mechanisms occur rapidly in developing HT.
Additionally, greater expression of the NPY Y1 receptor (Y1R) was observed in skeletal
muscle extracts from 7-week old SHRs, with no change in markers of adrenergic
innervation (α-AR and tyrosine hydroxylase). These data suggest that adrenergic
mechanisms do not contribute to HT at this age. The enhanced regulation of hindlimb
conductance by NPY in SHRs suggests that NPY and the Y1R are involved in the
development of HT.
A hallmark of hypertension is vascular remodeling which is characterized by
vascular stiffening and hypertrophy (3; 11; 24). NPY has been linked to vascular
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remodeling (1); yet the role of the SNS in regulating vascular stiffness remains
speculative. Using a modified Windkessel model, chapters 3 and 4 demonstrate that the
SNS is actively involved in the regulation of hindlimb vascular stiffness in male and
female rats. This stiffness was augmented in HT in both sexes; however, antagonism of
the Y1R produced no appreciable change in the measured stiffness in males, while
ganglionic ablation reduced stiffness in both sexes. Assessment of the Y1R control of
vascular stiffness in females was not performed for two reasons. First, research from our
lab has demonstrated that NPY plays little role baseline cardiovascular control in females
(12; 13). Secondly, no effect was observed by Y1R antagonism in males; therefore, it was
deemed unnecessary to examine the response in females. It is important to point out that
the regulation of the mechanical properties of the rat hindlimb appear to be different
between males and females in both normotension and hypertension (Figure 6.1).
Specifically, normotensive males (at least at 7 weeks of age) appear to regulate C and K
through the sympathetic nervous system, but not R. In contrast, sympathetic mechanisms
affect R and C in normotensive females without affecting K. Hypertension alters the
control in both males and females but in different ways. Male hypertensive animals retain
the neural control of C and K but gain control of R, while female animals lose the ability
to regulate C likely because of vascular remodeling, but retain control of R. These
differences highlight the dimorphism between males and females in vascular regulation
in both normotension and HT, but also underscore our limited understanding of its
complexity.
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Figure 6.1 ‒ Updated schematic depicting the mechanisms of control in both male and
female normotensive and hypertensive rats. See text for details. Dotted line represents
apparent lack of control (in males), dashed lines are speculated, but were not measured
(in males), and bolded appear to be augmented/dysregulated (in females).

136
Neuropeptide Y and the Y1R influence baseline vascular control in males (14), as
antagonism of the Y1R increased hindlimb vascular compliance. Chapter 3 demonstrated
that Y1R blockade did not alter vascular resistance. However, the measurements of
arterial pressure and flow here were made at the level of the aorta, versus the femoral
artery as in chapter 2. Vascular resistance reflects only the steady state component of
blood flow and acts through alterations in vessel diameter (25). Thus, the resistance of the
central vessels makes up a negligible part of total resistance, because of their relatively
large diameters, and it is reasonable to suspect that central vascular radii are under less
SNS control (31). Therefore, alterations in aortic flow following Y1R antagonism were
not expected.
The augmented vascular stiffness seen in female animals forms the basis for the
proposed sex-associated differences in cardiovascular regulation outlined in chapter 5.
The stiffer vascular beds of female animals suggests that female animals may rely on
mechanical rather than chemical regulation of the vasculature. Alteration of the stiffness
of the vasculature rather than the diameter of the blood vessels may increase the
contribution of changes in heart rate and cardiac contractility to regulate blood pressure.
This cardiac mechanism has been suggested previously. Using both lower body negative
pressure (7) and progressive tilt (29), females preferentially induce tachycardia rather
than increased vascular resistance. Additionally, reflexive increases in muscle
sympathetic nerve activity are blunted relative to males, which is consistent with
parasympathetic withdrawal occurring prior to sympathetic activation in the heart (8; 19;
28).
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Finally, hypertensive animals, both male and female, exhibited markedly stiffer
vessels compared to their normotensive counterparts. This observation was expected.
However, the fact that only the female hypertensive animals appeared to have lost the
neurogenic control over the vascular stiffness, is intriguing. Perhaps the augmented
stiffness imposed by the hyper-adrenergic state that characterizes hypertension (10; 32;
36) irreversibly stiffens the vasculature through remodeling, thereby preventing it from
relaxing. The mechanistic and teleology for this sex-based difference in SHR animals are
not known. Regardless, these data clearly demonstrate that in hypertension sex
differences in cardiovascular control are present.
In conclusion, two major themes are evident from this body of work. First, altered
neurovascular regulation during the early stages of HT is evident. Secondly, the ways in
which male and female animals regulate the cardiovascular system appear to be
fundamentally different. Expanding on the first finding, enhanced NPY mediated
hindlimb vascular conductance was observed in 7-week old male SHRs. These in vivo
observations were supported by an increased expression of Y1R in red vastus
homogenates from SHR while α-AR mechanisms were comparable to WKY control
animals. The increased vascular resistance and stiffness in the SHR were
sympathetically-mediated in both sexes, but NPY and the Y1R do not appear to be
involved. The augmented vascular stiffness in females relative to males was the first
indicator of the sexual dimorphism of cardiovascular control. Coupled with the lack of
baseline NPY/Y1R control (12; 13) and the modulation of sympathetic control with
ovariectomy (15), a situation arises whereby the stiffer vasculature of female animals
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would allow changes in heart rate to maintain blood pressure, while male animals utilize
increases in vascular resistance.

6.2

Limitations
A major limitation of this dissertation is the absence of measured sympathetic

nerve activity. Measurement of either renal or lumbar sympathetic nerve activity is
routinely done in the literature. Much of this dissertation assumes that sympathetic
outflow is elevated in the SHR animals. This assumption has been validated previously
(see (9) for a detailed review), yet direct measurement here would strengthen our
conclusions. Additionally, a direct measurement of sympathetic nerve activity would
have allowed us to verify that the hexamethonium produced a complete ganglionic
blockade. We can reasonably assume that complete ganglionic blockade occurred with
hexamethonium as previously published reports (16; 30) indicate that 20mg/kg was a
sufficient dose to completely block ganglionic neural transmission as measured in the
renal nerve in both SHR and WKY animals.
A second limitation here is rooted in the fact that the dichotomous mechanisms of
cardiovascular regulation being proposed are based on a finite number of observations
from different data sets. While precautions are taken to ensure consistency between
experiments, random variations are assured. The stiffness data presented were collected
such that experiments were run on half of the female animals followed by all of the male
animals, and finally the second half of the females. The unique timing of data collection
reduces the likelihood of bias in data collection (i.e. surgical precision) and bolsters our
confidence in the observations.
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Third, there is a possibility that the responses seen in an anaesthetized rat are not
physiological, due to blunted reflex control. This is a valid argument, and with many
barbiturate and gas forms of anaesthesia this holds true (23; 34). Here, a mixture of
urethane and α-chloralose was utilized as this cocktail has been shown to maintain reflex
cardiovascular control (20; 21). Additionally, data from our lab (Usselman et al., In
Press) indicates that this cocktail does not impair autonomic reflexes, as both light and
deep levels of anaesthesia did not impair sympathetic reflexes in response to lower body
negative pressure in rats.
As outlined in chapter 1, the RCKL model relies on pressure-volume relationships
to estimate the mechanical properties of the vasculature. Primarily, because these
properties represent the vasculature as a whole, we are unable to ascribe a specific level
of the vascular tree to a given component of the model (35). Additionally, a large
proportion of the resistance in the model is generated by resistance arterioles, but it is
unclear from the model how these vessels also contribute to the compliance of the
vascular bed. Further, the four components of this model represent an over simplification
of a complex physiologic system giving us a method to conceptualize the mechanical
properties. Additionally, because of the observed falls in MAP following Hex, changes in
C might reflect a shift along the same pressure-volume curve, and may not be indicative
of an actual change in the mechanical properties of the vasculature (i.e. shift of the
pressure-volume curve).
Finally, as the majority of the data were collected from adolescent animals, it can
be argued that the differences observed are due to variations in the growth patterns of the
animals and are therefore artifacts of the normal growth process. It is unlikely that the
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differences are artifacts, as the majority of animals tested were measured at the same
absolute age of 7 weeks. This age was chosen for two specific reasons. First, at the same
absolute age, WKY animals are heavier than SHR animals. Therefore had the animals
been matched by weight, as is often done, the WKY animals would have represented a
younger population of animals compared to the SHRs. Similarly, comparisons between
the sexes would be invalid, as weight matched females would be older relative to the
males. Secondly, at 7 weeks of age mild HT is evident in SHRs while other comorbidities, such as heart disease, dyslipidemia or insulin resistance, are absent (4; 6;
27). Thus, matching the age of the animals allows for between group comparisons with
little chance of growth artifact or co-morbidities factoring into the observations.

6.3

Future Directions
This dissertation outlines our attempts to understand the role of the SNS during

the development of HT. It highlights some key alterations in the vascular response to
sympathetic innervation, yet much work needs to be completed to broaden our
understanding of how these two critically integrated systems are regulated.
A critical first step needs to be to integrate neural recordings into the
methodologies described herein. Technological advances have led to the development of
in-dwelling telemetric devices, which allow for the continuous measurement of two
separate variables (i.e. blood pressure and sympathetic nerve activity). Using these
devices tocollect data from conscious animals eliminates any anesthetic effects and
allows for a longitudinal assessment of sympathetic hyperactivity and arterial pressure
augmentation. Furthermore, the effectiveness of interventions designed to either raise or
lower sympathetic activity (or blood pressure) can be evaluated.
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A role for NPY and the Y1R in the early stages of HT is implicated (chapter 2),
yet much work is required to ascertain the mechanisms responsible for this enhanced
regulation. To gain better insight into the roles of NPY and the Y1R in HT, chronic
receptor agonism/antagonism studies are required. Examining the molecular, cellular and
hemodynamic responses to chronic agonism/antagonism will help expose some the
mechanisms governing the development of HT.
The involvement of eatradiol (E2) in both sympathetic and cardiovascular
development is known (2; 5; 33). Characterizing E2’s role in regulating the mechanical
properties of the vascular wall and how the SNS functions differently during chronic (812 week) E2 manipulation, is unknown. Additionally, E2 supplementation in the form of
a continuous release pellet does not mimic the natural 4 day cycle of the rat (17; 26).
Thus, a more physiologic study of E2 should be made, which accounts for the cyclic
nature of this important hormone. Further, exploring how E2 and androgen manipulation
in male rats affects both the sympathetic and cardiovascular systems is required.
Chapter 5 of this dissertation proposes a novel mechanism of cardiovascular
control in young female rats. This supposition was based on a limited number of
observations; therefore a thorough investigation of this phenomenon should be made. In
order to ascertain whether female animals rely on central (cardiac) versus peripheral
(vascular resistance) mechanisms to maintain blood pressure during times of stress,
selective blockade of the heart and blood vessels is required. Selectively antagonizing
different aspects of the autonomic nervous system will allow for clarification of the
precise roles they have in cardiovascular regulation.
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6.4

Final Remarks
The involvement of the SNS in the development of HT is known and accepted (9;

22), yet the alterations in sympathetic control that occur early in the pathogenesis are less
well understood. We have shown that alterations in NPY signaling and the Y1R precede
changes in the adrenergic system. Additionally, the increased stiffness that is observed in
HT begins very early in the process, does not involve the Y1R and is a regulated property
of the vasculature that appears to be defective in female HT animals. Finally, the sexassociated differences in vascular stiffness and the regulation of the mechanical
properties of the vasculature may highlight a novel mechanism of vascular control in
young male and female animals. Evidence supporting this theory is mounting; however,
much work needs to be done to confirm these suppositions.
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Appendix A ‒ Supplementary Data
Chapter 3‒ Femoral Flow Variability
Figure A.1 depicts the fluctuations in femoral flow observed in the female
animals compared to male animals. The fluctuations were independent of changes in
pressure, heart rate and temperature. The flow would rise for 2-3 minutes and would then
fall. There was never a prolonged period of stability which prevented a stable baseline
from being collected.
Figure A.2 illustrates the variability among intact female animals, female animals
that were ovariectomized (OVX), ovariectomized + estrogen replacement (OVX+E2;
0.25mg 17β-estradiol [3-week release]) and male animals. The coefficient of variation
(CoV = standard deviation/mean) for hindlimb conductance (CFem=femoral flow/mean
arterial pressure) was calculated using 1000 consecutive heart beats at baseline and
following ganglionic antagonism with hexamethonium bromide (Hex; 25 mg/kg). The
variability was modulated by both E2 and the sympathetic nervous system, but the reason
for this variability is unknown.
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Figure A.1 ‒ Representative raw data tracings of female (A, B, C) and male (D, E, F)
spontaneously hypertensive rats. Note the large fluctuations in femoral flow (C) of
female rat, with little or no change in arterial pressure (A), or heart rate (B).
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Figure A.2 ‒ Coefficient of variation (CoV) for femoral conductance (CFem) amongst the
experimental groups at baseline and following sympathectomy with hexamethonium
bromide (Hex). * denotes P<0.05 versus baseline within-group; † denotes P<0.05 versus
intact male at baseline.

Chapter 5 ‒ Estrogen manipulation and vascular mechanics.
Table A.1 ‒ The absolute in vivo hemodynamic variables from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) that
were either ovariectomized (OVX) or ovariectomized and supplemented with estrogen (OVX+E2).
Strain
WKY

SHR

Variable
HR (beats/min)
MAP (mmHg)
QCaud (mL/min)
CCond (mL/min/mmHg)
HR (beats/min)
MAP (mmHg)
QCaud (mL/min)
CCond (mL/min/mmHg)

Intact
345±29
78±5
5.0±2.0
65±28
381±38
103±19*
3.5±1.6*
33±11*

OVX
399±20
75±10
6.6±3.9
94±61
340±43
86±13
4.4±1.3
51±12†

OVX+E
327±23
76±6
4.0±2.0
54±31
390±33*
109±27*
3.4±1.2
31±8‡

Values are mean ± Standard Deviation. HR = Heart Rate; MAP = Mean Arterial Pressure; QCond = Caudal Flow; CCond = Caudal
Conductance; R = Resistance; C = Compliance; K = Viscoelasticity; PWV = Pulse Wave Velocity. * denotes P<0.05 versus WKY (of
same group); † denotes P<0.05 versus Intact; ‡ denotes P<0.05 versus OVX.
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Figure A.3 ‒ Resistance (R), compliance (C), viscoelasticity (K) and pulse wave velocity
(PWV) in intact, ovariectomized (OVX) and ovariectomized supplemented with estrogen
(OVX+E2) Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Values are
mean ± standard deviation. * denotes P<0.05 versus WKY of same group, † denotes
P<0.05 versus OVX of same strain (both point to point comparisons). Main effect
statistics: a, P<0.05 versus WKY; b, P<0.05 versus OVX.
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Appendix B ‒ Ethics Approvals
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Appendix C ‒ Details of Western Blot Protocol
Approximately 70mg of frozen tissues were homogenized in 15 volumes
(approximately 1 mL) of extraction buffer (10mM Tris, 100mM NaCl, 1mM EDTA,
1mM EGTA Tetra Sodium, 1% Triton X-100, 10% Glycine, 0.1% SDS, 0.5% Sodium
Deoxycholate, 1% protease inhibitor cocktail (Sigma-Aldrich, Cat. No. P8340); pH =
7.4), and centrifuged at 16000g for 20 min in order to collect the supernatant as the tissue
extract. Sample homogenates were then stored at −70°C until the time of total protein
concentration determination (Bradford protein assay (1)) and electrophoresis. Equal
amounts of total protein (60 μg for Y1R and 120 μg for Tyrosine Hydroxylase (TH) and
α-AR) were run on 12% sodium dodecyl sulfate polyacrylamide gel (SDS PAGE)
overlaid with a 4% acrylamide stacking gel. A protein standard (Bio-Rad Cat. No. 1610376) was run along with the tissue homogenate. Following electrophoresis, the proteins
were transferred at constant voltage in cold transfer buffer (10% running buffer, 20%
methanol in ddH2O) to a polyvinylidene fluoride membrane (PVDF; Bio-Rad Cat. No.
162-0177). The membranes were wetted with methanol prior to protein transfer, and
subsequently blocked in a 5% non-fat milk solution in Tris buffered saline + 0.05%
Tween 20 (TTBS) (80mM Tris Base, 0.5M NaCl). Membranes were then incubated
overnight in primary antibody specific to either rat, human or mouse anti-Y1R (1:300,
affinity purified rabbit anti-mouse Y1R IgG, Alpha Diagnostic International, Cat. No.
NPY1R11-A, San Antonio, TX, USA), anti-α1-AR (1:400 affinity isolated rabbit, SigmaAldrich Cat. No. A270) or anti-TH (1:1000 purified rabbit polyclonal antibody,
Millipore, Cat. No. AB152, Billerica, MA, USA) in TTBS with 2% non-fat milk.
Membranes were washed 3 times in TTBS then incubated in secondary antibody (goat
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anti-rabbit, or anti-mouse; 1:3000) conjugated to horseradish peroxidase (HRP; Bio-Rad,
Cat. No. 170-6518) and Precision Protein StrepTactin-HRP Conjugate (1:10000; BioRad, Cat.No. 161-0380) in TTBS with 2% non-fat milk for 1 hour. After washing (TTBS;
3 times), the blots were developed using Immun-Star WesternC chemiluminescent (BioRad, Cat. No. 170-5070) and detected using a Bio-Rad ChemiDoc XRS system (Bio-Rad,
Cat. No. 170-8070) with a supersensitive 16-bit CCD. Images were analyzed using
Quantity One 1-D Analysis Software (Bio-Rad, Cat. No. 170-9600).

Reference List
1. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254, 1976.

155

Curriculum Vitae
Louis Mattar
PhD Candidate
Neurovascular Research Lab
School of Kinesiology
The University of Western Ontario
London, ON, N6A 3K7, Canada

Education
2006–Present

Ph.D., Neurovascular Research Laboratory, The School of
Kinesiology, Faculty of Health Sciences, The University of
Western Ontario. Supervisor: Dr. J. Kevin Shoemaker.
Doctoral Thesis: On the early onset of vascular stiffening and
sexual dimorphism of sympathetic control in the spontaneously
hypertensive rat

2004–2006

M.Sc., Cardiorespiratory and Vascular Dynamics Laboratory, The
Department of Kinesiology, The Faculty of Applied Health
Sciences, University of Waterloo. Supervisor: Dr. Richard L.
Hughson.
Masters Thesis: The Effects of 60 days of Head Down Bed Rest on
Vascular Health.

2000–2004

Honours B.Sc., Kinesiology, Pre-Health Professional Option,
University of Waterloo.

Specific Training
a)
2010

Specific Training Certifications
Certificate in University Teaching and Learning, Teaching Support
Center, The University of Western Ontario.

2008

Rodent Hemodynamics Workshop, By: ADInstruments, Transonic Systems
Inc., and Gwathmey Inc., Boston, USA.

2008

Advanced Teaching Program, The Teaching Support Center, The
University of Western Ontario.

2006

Certificate in animal care, The University of Western Ontario.

156
b)

Training Statement
During my Master’s degree, the bulk of my training focused on the quantification

of blood borne proteins associated with cardiovascular health/disease. Measurement of
these factors were completed using a variety of techniques including: enzyme-linked
immunosorbent assay (ELISA), radioimmuno assays (RIA), and immunofluorescence.
Through this experience, I became proficient in the set up, calibration, and collection of
non-invasive blood pressure (Finometer/Finapres), and echo Dopplar ultrasound
measurements of arterial structure and blood velocity (various ultrasound
machines/Multigon). Data was obtained using a Powerlab and Chart system
(ADInstruments).
My Doctoral research shifted my study from Human to animal (rat) research.
Training in animal care, handling, husbandry, anesthesia, and aseptic surgical techniques
(tracheal intubation, arterial and venous canulation, and perivascular flow probe
placement) were required, obtained, and mastered. I also became proficient in a variety of
non-invasive measurement techniques including: non-invasive blood pressure (CODA
System, Kent Scientific) and micro ultrasound imaging (Visual Sonic). Additionally, I
have become comfortable with the preparation, procedure, and analysis of western
blotting techniques.
The aforementioned techniques from my Master’s and Doctoral degrees are ones
that I have performed, and am proficient in. I have been fortunate enough to become
familiar with a variety of other techniques that, while I have not done them personally, I
feel confident in my ability to explain both their theory, practice and in many cases, their
analysis. These techniques include: microneurography, phlebotomy, functional magnetic
resonance imaging (fMRI) and wire myography.

Honours and Awards
2011

Graduate Thesis Award. The University of Western Ontario. $795.

2011

Ontario Exercise Physiology Student Presentation Award Finalist, Ontario
Exercise Physiology. $100.

157
2010

Kinesiology Travel Award. From The School of Kinesiology, The University
of Western Ontario. $700.

2010

Faculty of Health Sciences Travel Award. From The Faculty of Health
Sciences, The University of Western Ontario. $500.

2010

Carolyn tum Suden Professional Opportunity Award. From The American
Physiological Society. $500.

2009–10 Ontario Graduate Scholarship. From the Government of Ontario.
$15,000/year.
2009

American Physiological Society Travel Award. From The American
Physiological Society. $625

2009

Faculty of Health Sciences Travel Award. From The Faculty of Health
Sciences, The University of Western Ontario. $500.

2008–09 Ontario Graduate Scholarship. From the Government of Ontario.
$15,000/year.
2008

Faculty of Health Sciences Travel Award. From The Faculty of Health
Sciences, The University of Western Ontario. $500.

2008

Kinesiology Travel Award. From The School of Kinesiology, The University
of Western Ontario. $625.

2008

Society of Graduate Students Travel Subsidy. The Society of Graduate
Students, The University of Western Ontario. $400.

2008

Graduate Thesis Award. The University of Western Ontario. $544.

2008

Mercury Printing Poster Award. From the Western Research Forum, The
University of Western Ontario. $50.

2004–06 Master’s Studentship Award. From The Heart and Stroke Foundation of
Ontario. $18,000/year.

Professional Membership
The American Physiological Society
The Canadian Society for Exercise Physiology

158

Professional Service
a)

Conference Organization

2007

Canadian Society for Exercise Physiology (CSEP). The University of Western
Ontario.

2007

Ontario Exercise Physiology (OEP). The University of Western Ontario.

2005

Ontario Exercise Physiology (OEP). University of Waterloo.

b)

Committee Involvement

Graduate Student Level
2009–10

President, The Kinesiology Graduate Board, The University of Western
Ontario.

2009–10

Member, Graduate Student Teaching Assistant Nomination Committee, The
University of Western Ontario.

2009–10

Member, Western Research Forum Committee, The University of Western
Ontario.

2008–09

Treasurer, The Kinesiology Graduate Board, The University of Western
Ontario.

Department/School Level
2009–10

Graduate Student Member, Kinesiology Graduate Affairs Committee, The
University of Western Ontario.

2009–10

Graduate Student Member, Kinesiology Executive Management Committee,
The University of Western Ontario.

2007–10

Graduate Student Member, Kinesiology School Affairs Counsel, The
University of Western Ontario.

2005–06

Member, Kinesiology Graduate Student Association, University of
Waterloo.

Faculty Level
2009–10

Graduate Student Member, Faculty of Health Sciences Faculty Counsel, The
University of Western Ontario.

159

University Level
2008–10

Counsellor, The Society of Graduate Students, The University of Western
Ontario.

2005–06

Member-At-Large, Graduate Student Association, University of Waterloo.

Scholarly Activity
Summary:
Articles in Progress/Submitted: 5
Articles in peer-reviewed journals: 6
Published abstracts from professional meetings: 13
Poster Presentations at Professional Meetings: 10
Oral Presentations at Professional Meetings: 7
Other Oral Presentations: 4

a) Articles in Progress/Submitted:
1. Mattar, L. D.N. Jackson and Shoemaker, J.K. (Submitted). Estrogen and
sympathetic modulation of hindlimb blood flow variability in rats. To be submitted to
Applied Physiology Nutrition and Metabolism APNM 11-4.
2. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (submitted previously).
Sympathetic Contribution to Peripheral Vascular Stiffness in Young Female
Spontaneously Hypertensive Rats.
3. Mattar, L., Jackson, D.N., Ellis, C.G., Noble, E. and Shoemaker, J.K. (submitted
previously). Age-related changes in sympathetic control of hindlimb conductance
and blood pressure in young hypertensive rats.
4. Mattar, L. and Shoemaker, J.K. (In Progress). Increased vascular stiffness in
spontaneously hypertensive rats following estrogen supplementation. To be submitted
to Clinical and Experimental Pharmacology and Physiology.
5. Mattar, L., Zamir, M., and J.K. Shoemaker (In Progress). Y1 Receptor versus
sympathetic control of hindlimb vascular stiffness in spontaneously hypertensive rats.
To be submitted to AJP - Reg. Int. Comp. Phys.
b) Articles in peer-reviewed journals:
1. Usselman, C.W., Mattar, L., Junuzovic, J., Welch, I., and Shoemaker, J.K.
(Accepted). Intra-strain baroreflex variability in urethane/α-chloralose anaesthetized
male Sprague-Dawley rats. Applied Physiology Nutrition and Metabolism, APNM10-264.
2. Hodges, G.J., Mattar, L., Zuj, K, Greaves, D., Arbeille, P., Hughson, R.L., and
Shoemaker, J.K. (2010). WISE 2005: Prolongation of left ventricular pre-ejection
period with 56 days head-down bed rest in women. Experimental Physiology, 95(11):
1081.

160
3. Hodges, G.J., Jackson, D.N., Mattar, L., Johnson, J., and Shoemaker, J.K. (2009).
Neuropeptide Y and neurovascular control in skeletal muscle and skin. AJP –
Regulatory, Integrative and Comparative Physiology. 297: R546-R555.
4. Arbeille, P., Kerbeci, P., Mattar, L., Shoemaker, J.K., and Hughson, R.L. (2008).
Insufficient flow reductions during LBNP in both splanchnic and lower limbs is
associated with orthostatic intolerance after bedrest. AJP – Heart and Circulatory
Physiology. 295: H1846 - H1845.
5. Arbeille, P., Kerbeci, P., Mattar, L., Shoemaker, J.K., and Hughson, R.L. (2008).
WISE-2005 – Tibial and Gastrocnemius Vein, and Calf Tissue Response to LBNP
after a 60 day Bedrest with and without Counter-measures. Journal of Applied
Physiology. 104: 938-943.
6. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., Hughson, R.L.
(2007). WISE 2005: Stroke Volume Changes Contribute to the Pressor Response
During Ischemic Handgrip Exercise in Females. Journal of Applied Physiology. 103:
228 - 233.
c) Published abstracts from professional meetings:
1. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (2010). Vascular stiffness and
the sympathetic nervous system in young female rats. APNM, 35:S65.
2. Mattar L., Noble, E., and Shoemaker, J.K. (2010). Estrogen and sympathetic
modulation of hindlimb blood flow variability in rats. FASEB Journal. 24:1039.13.
3. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Betaarrestin and vasomotor control in the spontaneously hypertensive rat. FASEB Journal.
23:1017.45.
4. Usselman, C.W., Welch, I., Mattar, L., and Shoemaker, J.K. (2009). Effect of depth
of anaesthesia and postganglionic sympathetic blockade on reflex heart rate control in
rodents during lower body negative pressure. FASEB Journal. 23:609.11.
5. Mattar L., Jackson, D.N., and Shoemaker, J.K. (2008). Neuropeptide Y And AgeRelated Development of Hypertension in the Rat. FASEB Journal. 22:968.18.
6. Edgell, H., Greaves, D., Mattar, L., Arbeille, P., Custaud, M.A., and Hughson, R.L.
(2008). WISE-2005: Changes in cardiovascular variables due to increasing levels of
adrenergic stimulation in women according to phase of menstruation. Committee on
Space Research.
7. Hughson, R.L., Shoemaker, J.K., Arbeille, P., Dyson, K.S., Edgell, H., Kerbeci, P.,
Mattar, L., Zuj, K., and Greaves, D.K. (2007). WISE-2005: Vascular Responses to
60-Day Bed Rest. Journal of Gravitational Physiology.
8. Shoemaker, J.K., Arbeille, P., Kerbeci, P., Mattar, L., and Hughson, R.L. (2007).
WISE-2005: Impact of 60-Day Bed Rest on Ischemic Exercise Pressor Response in
Females. Journal of Gravitational Physiology.
9. Hughson, R.L., Kerbeci, P., Arbeille, P., Mattar, L., and Shoemaker, J.K. (2006).
WISE-2005: Integrative Cardiovascular Responses with LBNP During 60-Day Bed
Rest in Women. Journal of Gravitational Physiology.
10. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., and Hughson, R.L.
(2006). WISE 2005: pressor responses to fatiguing handgrip are related to cardiac
output and not to systemic vascular resistance APNM, 31:S79.

161
11. Shoemaker, J.K., Mattar, L., Kerbeci, P., Trotter, S., Arbeille, P., Hughson, R.L.
(2006). WISE 2005: Does Cardiac Output Contribute to The Pressor Response
During Isometric Handgrip Exercise in Humans? Medicine & Science in Sports &
Exercise. 38(11) Suppl 1:S17.
12. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2006).
WISE-2005: 60 days head-down bed rest causes a shift towards a pro-artherosclerotic
environment. FASEB Journal, 20(5):A1254.
13. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2005).
WISE-2005: 60 Days Head-Down Bed Rest Causes and Increase in Angiotensin II.
Canadian Journal of Applied Physiology 30:S53.
d) Poster Presentations at Professional Meetings:
1. Mattar, L., Gimon, T., Zamir, M., and J.K. Shoemaker (2010). Vascular stiffness and
the sympathetic nervous system in young female rats. The Canadian Society for
Exercise Physiology; Toronto, ON; November 2010.
2. Mattar L., Noble, E., and Shoemaker, J.K. (2010). Estrogen and sympathetic
modulation of hindlimb blood flow variability in rats. Experimental Biology;
Anaheim, CA; April 2010.
3. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Betaarrestin and vasomotor control in the spontaneously hypertensive rat. J. Allen Taylor
International Prize in Medicine: Cardiovascular Research; London, Ontario;
November 2009.
4. Mattar, L., Noble, E., Shoemaker, J.K. (2009). Estrogen and the development of
hypertension in the female spontaneously hypertensive rats. APS Conference: Sex and
Gender in Cardiovascular-Renal Physiology and Pathophysiology; Broomfield, CO;
July 2009.
5. Mattar L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Betaarrestin and vasomotor control in the spontaneously hypertensive rat. Experimental
Biology; New Orleans, LA; April 2009.
6. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Neuropeptide Y And AgeRelated Development of Hypertension in the Rat. Experimental Biology; Dan Diego,
CA; April 2008.
7. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Neuropeptide Y And AgeRelated Development of Hypertension in the Rat. Western Research Forum; London,
ON; February 2008.
8. Mattar L., Jackson, D.N. and Shoemaker, J.K. (2008). Enhanced Constrictor
Response to Neuropeptide Y in the 7 week old Rat. ARGC/FHS Symposium on aging;
London, ON; February 2008.
9. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson., R.L. (2006).
WISE-2005: 60 days head-down bed rest causes a shift towards a pro-artherosclerotic
environment. Experimental Biology; San Francisco, CA; April 2006.
10. Mattar, L.; Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2005).
WISE-2005: 60 Days Head-Down Bed Rest Causes and Increase in Angiotensin II.
Canadian Society for Exercise Physiology; Gatineau, QC; November 2005.

162
e) Oral presentations at Professional Meetings:
1. Mattar, L. and Shoemaker, J.K. (2011). Sexual dimorphism and cardiovascular
regulation in rats. Western Research Forum; London, ON; February 2011.
2. Mattar, L. and Shoemaker, J.K. (2011). Evidence for sexual dimorphism in
cardiovascular regulation in rats. Ontario Exercise Physiology; Barrie, ON; January
2010.
3. Mattar, L., Jackson, D.N., Noble, E., and Shoemaker, J.K. (2010). Modulation of
hindlimb blood flow variability by estrogen and the sympathetic nervous system in
rats. Ontario Exercise Physiology; Barrie, ON; January 2010.
4. Mattar, L., Jackson, D.N., Ellis, C.G., Noble, E., and Shoemaker, J.K. (2009). Betaarrestin and vascular control in hypertension. Western Research Forum; London, ON;
January 2009.
5. Mattar, L., Jackson, D.N., and Shoemaker, J.K. (2009). Neuropeptide Y And AgeRelated Development of Hypertension in the Rat. Ontario Exercise Physiology;
Barrie, ON; January 2009.
6. Mattar, L., Jackson, D.N., and Shoemaker, J.K. (2008). Enhanced Constrictor
Response to Neuropeptide Y in the Spontaneously Hypertensive Rat. Ontario
Exercise Physiology; Barrie, ON; January 2008.
7. Mattar, L., Rush, J.W.E., Shoemaker, J.K., Arbeille, P., and Hughson, R.L. (2006).
WISE 2005: 60 Days Head down bed rest causes an increase in oxidative stress.
Ontario Exercise Physiology; Barrie, ON; January 2006.
f) Other Oral Presentations:
1. Presentation for Mrs. Kelly Sauve Grade 12 University Biology Preparation class. “A
career in school: Options for after University”. Dorchester High School; Dorchester,
ON; December 2008.
2. Lecture for Dr. H. Prapavessis 2nd/3rd year statistics (KIN 332a). The University of
Western Ontario. London, ON; October 2007.
3. Presentation for Ms. Jan Farquhar Grade 8 gifted class. “Why I like science”. Charles
R. Beaudoin Public School; Oakville, ON; June 2007.
4. Lecture for Dr. Timothy Wilson 2nd/3rd year anatomy. Anatomy of the Heart and
Lungs. The University of Western Ontario; London, ON; November 2006.

